{
    "id": 3068,
    "name": "glioblastoma multiforme",
    "source": "DOID",
    "definition": "An astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has_material_basis_in abnormally proliferating cells derives_from multiple cell types including astrocytes and oligondroctyes. [url:http\\://cancergenome.nih.gov/cancersselected/glioblastomamultiforme, url:http\\://en.wikipedia.org/wiki/Glioblastoma_multiforme, url:https\\://www.ncbi.nlm.nih.gov/pubmed/20129251, url:https\\://www.ncbi.nlm.nih.gov/pubmed/23029035]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "3075",
        "3080"
    ],
    "termId": "DOID:3068",
    "evidence": [
        {
            "id": 564,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of glioblastoma (PMID: 23553846).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 726,
                "therapyName": "EMD 1214063",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 336,
                    "pubMedId": 23553846,
                    "title": "EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23553846"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 848,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 2-Methoxyestradiol (2ME2) inhibited tumor-induced angiogenesis and reduced tumor growth in PTEN reconstituted GBM cell lines and mouse models (PMID: 24162827).",
            "molecularProfile": {
                "id": 683,
                "profileName": "PTEN wild-type"
            },
            "therapy": {
                "id": 1341,
                "therapyName": "2-Methoxyestradiol",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 492,
                    "pubMedId": 24162827,
                    "title": "PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1\u03b1 suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24162827"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 997,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, CCT128930 prevented tumor growth in a PTEN-null human glioblastoma cell line xenograft model (PMID: 21191045).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 1445,
                "therapyName": "CCT128930",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 692,
                    "pubMedId": 21191045,
                    "title": "Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21191045"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1082,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Stivarga, (regorafenib), inhibited tumor growth in cell line xenograft models of glioblastoma multiforme (PMID: 21170960).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 318,
                    "pubMedId": 21170960,
                    "title": "Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21170960"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1103,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) treatment resulted in a strong antitumoral effect in GBM cell lines with high levels of Src phosphorylation (PMID: 19098899).",
            "molecularProfile": {
                "id": 1875,
                "profileName": "SRC positive"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 845,
                    "pubMedId": 19098899,
                    "title": "Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19098899"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1149,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Adavosertib (MK-1775) and radiation therapy synergized to inhibit tumor growth in a human glioblastoma multiforme cell line xenograft model harboring mutant TP53 (PMID: 21992793).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 4186,
                "therapyName": "Adavosertib + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 898,
                    "pubMedId": 21992793,
                    "title": "Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21992793"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1232,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, inhibition of Notch2 signaling through the gamma-secretase inhibitor, GSI-18, blocked tumor growth and prolonged survival in mouse xenograft models of glioblastoma expressing an activated form of the NOTCH2 receptor (PMID: 19904829).",
            "molecularProfile": {
                "id": 2335,
                "profileName": "NOTCH2 act mut"
            },
            "therapy": {
                "id": 1662,
                "therapyName": "GSI-18",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 971,
                    "pubMedId": 19904829,
                    "title": "NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19904829"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1442,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In multiple Phase II clinical trials, Sutent (sunitinib) failed to demonstrate any benefit in patients with glioblastoma with or without concurrent bevacizumab treatment (PMID: 24424564, PMID: 23086433).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 1284,
                    "pubMedId": 24424564,
                    "title": "Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24424564"
                },
                {
                    "id": 1285,
                    "pubMedId": 23086433,
                    "title": "Continuous daily sunitinib for recurrent glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23086433"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1476,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "RNA editing is a significant regulator of gene expression and improper editing has been linked to a variety of disease states. Preclinical studies of upregulated RNA editing genes like ADARB1 in cancer cell lines suggests their potential value as therapeutic gene targets (PMID: 23737728).",
            "molecularProfile": {
                "id": 2595,
                "profileName": "ADARB1 amp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1135,
                    "pubMedId": 23737728,
                    "title": "RNA editing and drug discovery for cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23737728"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1545,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells harboring a MSH6 T1219I mutation were resistant to Temodar (temozolomide) in cell culture (PMID: 19584161).",
            "molecularProfile": {
                "id": 2665,
                "profileName": "MSH6 T1219I"
            },
            "therapy": {
                "id": 1141,
                "therapyName": "Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1465,
                    "pubMedId": 19584161,
                    "title": "MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19584161"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1601,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, siRNA inhibition of PMRT5 in PMRT5-overexpressing glioblastoma cells resulted in cell cycle arrest, decreased proliferation, and decreased migration in cell culture, suggesting that PMRT5 may be a promising therapeutic target (PMID: 24453002).",
            "molecularProfile": {
                "id": 2738,
                "profileName": "PRMT5 over exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1619,
                    "pubMedId": 24453002,
                    "title": "Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24453002"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1796,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Enzastaurin (LY317615) demonstrated efficacy by suppressing proliferation of cultured cells and growth in cell line xenograft models of glioblastoma (PMID: 16103100).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1682,
                "therapyName": "Enzastaurin",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2084,
                    "pubMedId": 16103100,
                    "title": "The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16103100"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1860,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) and Iressa (gefitinib) acted synergistically to decrease downstream signaling activity and inhibit cell growth of glioblastoma cell lines with EGFR and PDGFRA coamplification (PMID: 22323597).",
            "molecularProfile": {
                "id": 4004,
                "profileName": "EGFR amp PDGFRA amp"
            },
            "therapy": {
                "id": 2483,
                "therapyName": "Gefitinib + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2352,
                    "pubMedId": 22323597,
                    "title": "Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22323597"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1980,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial that supported FDA approval, treatment with Avastin (bevacizumab) resulted in an objective response rate of 25.9% (22/85) with a mean duration of response of 4.2 months in patients with glioblastoma (PMID: 19897538).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 667,
                "therapyName": "Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2421,
                    "pubMedId": 19897538,
                    "title": "FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19897538"
                },
                {
                    "id": 15584,
                    "pubMedId": null,
                    "title": "Avastin (bevacizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2155,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cannabidiol was demonstrated to inhibit ID1 gene transcription and subsequent cell migration and invasion in cultured glioblastoma cells over expressing Id1 (PMID: 23243024).",
            "molecularProfile": {
                "id": 2610,
                "profileName": "ID1 over exp"
            },
            "therapy": {
                "id": 2632,
                "therapyName": "Cannabidiol",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2665,
                    "pubMedId": 23243024,
                    "title": "Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23243024"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2209,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) inhibited flank tumor growth in a patient-derived xenograft model of glioblastoma multiforme (GBM) with MYC amplification, but had no efficacy in brain GBM xenograft tumors due to limited distribution across the blood-brain barrier (PMID: 25609063).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2769,
                    "pubMedId": 25609063,
                    "title": "The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25609063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2212,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Adavosertib (MK-1775) and Temodar (temozolomide) demonstrated anti-tumor activity in flank tumors in a patient-derived xenograft model of glioblastoma multiforme with MYC amplification, but had limited efficacy in brain tumor xenografts (PMID: 25609063).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 2713,
                "therapyName": "Adavosertib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2769,
                    "pubMedId": 25609063,
                    "title": "The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25609063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2254,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) induced apoptosis and inhibited growth in glioblastoma cells in culture and in cell line xenograft models (PMID: 25378936).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2836,
                    "pubMedId": 25378936,
                    "title": "The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25378936"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2501,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human glioblastoma cell lines with a CDKN2A/CDKN2C codeletion demonstrated sensitivity to Palbociclib (PD0332991) (PMID: 20534551).",
            "molecularProfile": {
                "id": 8470,
                "profileName": "CDKN2A del CDKN2C del"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3184,
                    "pubMedId": 20534551,
                    "title": "Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20534551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9367,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited proliferation of patient-derived glioblastoma cells harboring homozygous deletion of CDKN2A and CDKN2C in culture (PMID: 22711607).",
            "molecularProfile": {
                "id": 8470,
                "profileName": "CDKN2A del CDKN2C del"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3561,
                    "pubMedId": 22711607,
                    "title": "p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22711607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2620,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-04691502 inhibited Akt phosphorylation, resulted in growth inhibition of PTEN-null glioblastoma cells in culture and in cell line xenograft models (PMID: 21750219).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 865,
                "therapyName": "PF-04691502",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 226,
                    "pubMedId": 21750219,
                    "title": "PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21750219"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2712,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells expressing the FGFR3-TACC3 fusion in culture (PMID: 23298836).",
            "molecularProfile": {
                "id": 10071,
                "profileName": "FGFR3 - TACC3"
            },
            "therapy": {
                "id": 2427,
                "therapyName": "U0126",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3393,
                    "pubMedId": 23298836,
                    "title": "The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23298836"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2713,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells over-expressing Fgfr3 in culture (PMID: 23298836).",
            "molecularProfile": {
                "id": 8807,
                "profileName": "FGFR3 over exp"
            },
            "therapy": {
                "id": 2427,
                "therapyName": "U0126",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3393,
                    "pubMedId": 23298836,
                    "title": "The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23298836"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2786,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LYS6KAKT1 inhibited phosphorylation of p70S6 kinase in mice engrafted with glioblastoma cells (Mol Cancer Ther 2011;10(11 Suppl):Abstract nr B117).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2080,
                "therapyName": "LYS6KAKT1",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1989,
                    "pubMedId": null,
                    "title": "Abstract B117: Early detection of a metabolic tumor response to p70S6 kinase/AKT inhibition by LYS6KAKT1 using in vivo choline proton magnetic resonance spectroscopy.",
                    "url": "http://mct.aacrjournals.org/content/10/11_Supplement/B117.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2829,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CC-115 increased survival of patient derived xenograft models of glioblastoma (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1755).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1000,
                "therapyName": "CC-115",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4113,
                    "pubMedId": null,
                    "title": "TORK/DNA-PK inhibitor CC-115 is effective as a single agent in a subset of glioblastoma patient-derived cancer stem cells and xenografts and potentiates temozolomide therapy",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/1755.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3210,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of glioblastoma xenografts (PMID: 26005526).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2545,
                "therapyName": "BMS-906024",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3681,
                    "pubMedId": 26005526,
                    "title": "Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26005526"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3237,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Caprelsa (vandetanib), in combination with Temodar (temozolomide) and radiation therapy, demonstrated a significant increase in PFS and OS in glioblastoma patients harboring IDH1 R132H compared to glioblastoma patients without IDH1 R132H (PMID: 25910950).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 3094,
                "therapyName": "Temozolomide + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3688,
                    "pubMedId": 25910950,
                    "title": "A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25910950"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3238,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Caprelsa (vandetinib), in combination with radiation therapy and Temodar (temozolomide), demonstrated no difference in PFS and OS when compared to radiation therapy and Temodar (temozolomide) alone in glioblastoma patients (PMID: 25910950).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3094,
                "therapyName": "Temozolomide + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3688,
                    "pubMedId": 25910950,
                    "title": "A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25910950"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3239,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Caprelsa (vandetinib), in combination with radiation therapy and Temodar (temozolomide), demonstrated no difference in PFS and OS in glioblastoma patients harboring EGFR amplification versus glioblastoma patients without EGFR amplification (PMID: 25910950).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 3094,
                "therapyName": "Temozolomide + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3688,
                    "pubMedId": 25910950,
                    "title": "A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25910950"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3240,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Caprelsa (vandetinib), in combination with radiation therapy and Temodar (temozolomide), demonstrated no difference in PFS and OS when compared between glioblastoma patients negative for PTEN versus those positive for PTEN (PMID: 25910950).",
            "molecularProfile": {
                "id": 2077,
                "profileName": "PTEN negative"
            },
            "therapy": {
                "id": 3094,
                "therapyName": "Temozolomide + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3688,
                    "pubMedId": 25910950,
                    "title": "A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25910950"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3321,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tanibirumab (TTAC-0001) inhibited angiogenesis and tumor growth in human glioblastoma cell line xenograft models (PMID: 26325365).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2515,
                "therapyName": "Tanibirumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3734,
                    "pubMedId": 26325365,
                    "title": "Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26325365"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9358,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Depatuxizumab mafodotin (ABT-414) resulted in an overall response rate of 6.7% (3/59; 1 complete response and 2 partial responses), stable disease in 41% (27/66), and a progression-free survival rate of 28.8% (95% CI 18.5, 39.9%) at 6 months in patients with EGFR-amplified recurrent glioblastoma (PMID: 29075855; NCT01800695).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7123,
                    "pubMedId": null,
                    "title": "EFFICACY OF A NOVEL ANTIBODY-DRUG CONJUGATE (ADC), ABT-414, AS MONOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (EGFRamp), RECURRENT GLIOBLASTOMA (rGBM)",
                    "url": "http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi2.3.abstract?sid=ef6007c0-0537-40d1-920d-fceb55d555f5"
                },
                {
                    "id": 10363,
                    "pubMedId": 29075855,
                    "title": "Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29075855"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3910,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK1838705A inhibited cell growth and prevented tumor growth via apoptotic induction in glioma cells in both culture and xenograft models (PMID: 26238593).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2739,
                "therapyName": "GSK1838705A",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4285,
                    "pubMedId": 26238593,
                    "title": "GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26238593"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3976,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioma cells were sensitive to TAE226 in culture and in cell line xenograft models, resulting in inhibition of both Igf-1r phosphorylation and downstream signaling and an improved survival rate (PMID: 17431114).",
            "molecularProfile": {
                "id": 578,
                "profileName": "IGF1R wild-type"
            },
            "therapy": {
                "id": 2086,
                "therapyName": "TAE226",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1918,
                    "pubMedId": 17431114,
                    "title": "Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17431114"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4005,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Balversa (erdafitinib) treatment resulted in tumor reduction and stable disease in 2 glioblastoma multiforme patients harboring FGFR3-TACC3 fusion (PMID: 25609060).",
            "molecularProfile": {
                "id": 10071,
                "profileName": "FGFR3 - TACC3"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4364,
                    "pubMedId": 25609060,
                    "title": "Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25609060"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4004,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Balversa (erdafitinib) treatment resulted in partial response in a glioblastoma patient harboring FGFR3-TACC3 fusion (PMID: 26324363; NCT01703481).",
            "molecularProfile": {
                "id": 10071,
                "profileName": "FGFR3 - TACC3"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4363,
                    "pubMedId": 26324363,
                    "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26324363"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4204,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MPS1-IN-3, in combination with Oncovvin (vincristine), inhibited cell growth of glioblastoma cells in culture and in xenograft GBM models (PMID: 23940287).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3456,
                "therapyName": "MPS1-IN-3 + Vincristine",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4420,
                    "pubMedId": 23940287,
                    "title": "Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23940287"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4331,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase II trial, FMO4/OSBPL3 expression was associated with favorable overall survival in recurrent glioblastoma patients treated with a combination of Avastin (bevacizumab) and Lomustine (PMID: 26762204).",
            "molecularProfile": {
                "id": 17816,
                "profileName": "FMO4 pos OSBPL3 pos"
            },
            "therapy": {
                "id": 2118,
                "therapyName": "Bevacizumab + Lomustine",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4498,
                    "pubMedId": 26762204,
                    "title": "Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26762204"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4332,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase II trial, IDH1 mutation correlated with favorable overall survival in recurrent glioblastoma patients treated with a combination of Avastin (bevacizumab) and Lomustine (PMID: 26762204).",
            "molecularProfile": {
                "id": 1781,
                "profileName": "IDH1 mutant"
            },
            "therapy": {
                "id": 2118,
                "therapyName": "Bevacizumab + Lomustine",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4498,
                    "pubMedId": 26762204,
                    "title": "Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26762204"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4629,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PRN1371 treatment resulted in tumor regression in PDX models of glioblastoma (Eu J Cancer 2014 Vol 50, Suppl 6:157).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3583,
                "therapyName": "PRN1371",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4638,
                    "pubMedId": null,
                    "title": "Irreversible Covalent Pan-FGFR Inhibitors are Highly Efficacious Against FGFR-dependent Cancers",
                    "url": "http://www.ejcancer.com/article/S0959-8049%2814%2970609-4/pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4683,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioma cell line treated with PHM16 demonstrated inhibition of Fak autophosphorylation and decreased cell growth via cell cycle arrest in culture (PMID: 24657306).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 3595,
                "therapyName": "PHM16",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4667,
                    "pubMedId": 24657306,
                    "title": "Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24657306"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4757,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells treated with COG112 demonstrated a decrease in cell proliferation (PMID: 21297667).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3607,
                "therapyName": "COG112",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4698,
                    "pubMedId": 21297667,
                    "title": "Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21297667"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4758,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells treated with a combination of LB100 and radiotherapy resulted in inhibition of Pp2a activity, decreased tumor growth, and increased cell survival (PMID: 25939762).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3514,
                "therapyName": "LB-100",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4699,
                    "pubMedId": 25939762,
                    "title": "Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939762"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4882,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased expression of Egfr and Rictor using siRNA resulted in increased sensitivity to Oncovin (vincristine) in glioblastoma cell lines in culture, including both PTEN wild-type and PTEN mutant cell lines (PMID: 23555046).",
            "molecularProfile": {
                "id": 29889,
                "profileName": "EGFR dec exp RICTOR dec exp"
            },
            "therapy": {
                "id": 1631,
                "therapyName": "Vincristine",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4768,
                    "pubMedId": 23555046,
                    "title": "Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23555046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4883,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased expression of Egfr and Rictor using siRNA resulted in increased sensitivity to Temodar (temozolomide) in glioblastoma cell lines in culture, including both PTEN wild-type and PTEN mutant cell lines (PMID: 23555046).",
            "molecularProfile": {
                "id": 29889,
                "profileName": "EGFR dec exp RICTOR dec exp"
            },
            "therapy": {
                "id": 1141,
                "therapyName": "Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4768,
                    "pubMedId": 23555046,
                    "title": "Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23555046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4982,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with imetelstat resulted in increased cell death in glioblastoma multiforme (GBM) cells in culture, and decreased tumor growth in xenograft models (PMID: 20048334).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3710,
                "therapyName": "Imetelstat",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4825,
                    "pubMedId": 20048334,
                    "title": "The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20048334"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5181,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cell lines harboring PIK3CA H1047Y demonstrated increased sensitivity to YM-204 induced growth inhibition (PMID: 24718026).",
            "molecularProfile": {
                "id": 3652,
                "profileName": "PIK3CA H1047Y"
            },
            "therapy": {
                "id": 2967,
                "therapyName": "YM-024",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4902,
                    "pubMedId": 24718026,
                    "title": "Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24718026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5182,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YM-024 inhibited proliferation and anchorage-independent growth of glioblastoma cell lines with elevated Pik3ca protein level in culture (PMID: 24718026).",
            "molecularProfile": {
                "id": 20299,
                "profileName": "PIK3CA over exp"
            },
            "therapy": {
                "id": 2967,
                "therapyName": "YM-024",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4902,
                    "pubMedId": 24718026,
                    "title": "Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24718026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5183,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YM-024 did not inhibit proliferation of glioblastoma cell lines harboring PIK3CA V344G in culture (PMID: 24718026).",
            "molecularProfile": {
                "id": 3729,
                "profileName": "PIK3CA V344G"
            },
            "therapy": {
                "id": 2967,
                "therapyName": "YM-024",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4902,
                    "pubMedId": 24718026,
                    "title": "Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24718026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5220,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased Bcl2 expression through Bcl2-siRNA silencing potentiated the anti-tumor effect of Taxol (paclitaxel) in cell line xenograft models of glioblastoma (PMID: 19473291).",
            "molecularProfile": {
                "id": 20309,
                "profileName": "BCL2 dec exp"
            },
            "therapy": {
                "id": 1103,
                "therapyName": "Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4927,
                    "pubMedId": 19473291,
                    "title": "Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19473291"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5278,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Zolinza (vorinostat) and Velcade (bortezomib) synergized to decrease cell viability, DNA fragmentation and elevate caspase 9 activity in several human glioblastoma cell lines in culture and in xenograft models of one human glioblastoma cell line (PMID: 26804704).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3810,
                "therapyName": "Bortezomib + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4978,
                    "pubMedId": 26804704,
                    "title": "Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26804704"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5279,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells treated with a combination of Zolinza (vorinostat) and Marizomib resulted in a synergistic effect, demonstrating decreased cell viability, DNA fragmentation and elevated caspase 9 activity in both culture and xenograft models (PMID: 26804704).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3812,
                "therapyName": "Marizomib + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4978,
                    "pubMedId": 26804704,
                    "title": "Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26804704"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5280,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells treated with a combination of Farydak (panobinostat) and Velcade (bortezomib) resulted in a synergistic effect, demonstrating decreased cell viability in culture (PMID: 26804704).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3811,
                "therapyName": "Bortezomib + Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4978,
                    "pubMedId": 26804704,
                    "title": "Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26804704"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5281,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells treated with a combination of Farydak (panobinostat) and Marizomib resulted in a synergistic effect, demonstrating decreased cell viability in culture (PMID: 26804704).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3813,
                "therapyName": "Marizomib + Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4978,
                    "pubMedId": 26804704,
                    "title": "Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26804704"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5293,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SEN-450 inhibited tumor growth in glioblastoma multiforme cell line xenograft models following tumor debulking with Temodar (temozolomide) treatment (PMID: 22072503).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3821,
                "therapyName": "SEN-450 + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4994,
                    "pubMedId": 22072503,
                    "title": "In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22072503"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5402,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PKI-402 inhibited tumor growth in PTEN-negative glioblastoma multiforme cell line xenograft models (PMID: 20371716).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 3857,
                "therapyName": "PKI-402",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5041,
                    "pubMedId": 20371716,
                    "title": "Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20371716"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5446,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LLL12 inhibited Stat3 signaling and proliferaion, induced apoptosis in glioblastoma cell lines demonstrating constitutive Stat3 activation in culture (PMID: 21526200).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3592,
                "therapyName": "LLL12",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5059,
                    "pubMedId": 21526200,
                    "title": "The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21526200"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5508,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WP1066 inhibited Stat3 signaling and cell survival in glioblastoma patient-derived tumor cells demonstrating constitutive activation of Stat3 in culture, and suppressed tumor growth in patient-derived xenograft (PDX) models (PMID: 23262510).",
            "molecularProfile": {
                "id": 17818,
                "profileName": "STAT3 act mut"
            },
            "therapy": {
                "id": 2784,
                "therapyName": "WP1066",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5078,
                    "pubMedId": 23262510,
                    "title": "On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23262510"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13383,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "IDH1 mutations aid in the diagnosis of secondary grade IV glioblastomas (NCCN.org).",
            "molecularProfile": {
                "id": 1781,
                "profileName": "IDH1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6031,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In multiple clinical studies, including two meta-analyses, IDH1 mutations were associated with a greater overall survival and progression-free survival in patients with glioblastoma (PMID: 23904262, PMID: 26945349, PMID: 20560678).",
            "molecularProfile": {
                "id": 1781,
                "profileName": "IDH1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5242,
                    "pubMedId": 23904262,
                    "title": "IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23904262"
                },
                {
                    "id": 5243,
                    "pubMedId": 26945349,
                    "title": "Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26945349"
                },
                {
                    "id": 5244,
                    "pubMedId": 20560678,
                    "title": "Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20560678"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6037,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22287,
                "profileName": "EGFR act mut EGFR amp PTEN R308C"
            },
            "therapy": {
                "id": 4008,
                "therapyName": "Gefitinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6038,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring mutations in EGFR (EGFRvIII, A289T) and PTEN (I253N, N69D) in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22288,
                "profileName": "EGFR A289T EGFR act mut PTEN N69D PTEN I253N"
            },
            "therapy": {
                "id": 4008,
                "therapyName": "Gefitinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6040,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification and EGFR G719A in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22289,
                "profileName": "EGFR G719A EGFR amp"
            },
            "therapy": {
                "id": 4008,
                "therapyName": "Gefitinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6042,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 4008,
                "therapyName": "Gefitinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6043,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 4009,
                "therapyName": "BMS-754807 + Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6044,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification and EGFR G719A in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22289,
                "profileName": "EGFR G719A EGFR amp"
            },
            "therapy": {
                "id": 4009,
                "therapyName": "BMS-754807 + Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6045,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22287,
                "profileName": "EGFR act mut EGFR amp PTEN R308C"
            },
            "therapy": {
                "id": 4009,
                "therapyName": "BMS-754807 + Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6046,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR (A289T, EGFRvIII) and PTEN (N69D, I253N) mutations in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22288,
                "profileName": "EGFR A289T EGFR act mut PTEN N69D PTEN I253N"
            },
            "therapy": {
                "id": 4009,
                "therapyName": "BMS-754807 + Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6048,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) inhibited survival of InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6049,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) inhibited survival of InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6050,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII were resistant to Linsitinib (OSI-906)-induced growth inhibition in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 798,
                "therapyName": "Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6051,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII were resistant to BMS-754807-induced growth inhibition in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 686,
                "therapyName": "BMS-754807",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6052,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) combination treatment did not improve growth inhibition compared to single therapy in InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 4008,
                "therapyName": "Gefitinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6053,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 combination treatment did not improve growth inhibition compared to single therapy in InsR- and IGF1R-negative glioblastoma cell lines harboring EGFR amplification and EGFRvIII in culture (PMID: 26561558).",
            "molecularProfile": {
                "id": 22292,
                "profileName": "EGFR act mut EGFR amp IGF1R neg INSR neg"
            },
            "therapy": {
                "id": 4009,
                "therapyName": "BMS-754807 + Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5255,
                    "pubMedId": 26561558,
                    "title": "InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26561558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6202,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).",
            "molecularProfile": {
                "id": 22832,
                "profileName": "ATRX loss"
            },
            "therapy": {
                "id": 1009,
                "therapyName": "Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5444,
                    "pubMedId": 26936505,
                    "title": "ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936505"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6203,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).",
            "molecularProfile": {
                "id": 22832,
                "profileName": "ATRX loss"
            },
            "therapy": {
                "id": 1074,
                "therapyName": "Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5444,
                    "pubMedId": 26936505,
                    "title": "ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936505"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6204,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).",
            "molecularProfile": {
                "id": 22832,
                "profileName": "ATRX loss"
            },
            "therapy": {
                "id": 942,
                "therapyName": "Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5444,
                    "pubMedId": 26936505,
                    "title": "ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936505"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6213,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture, resulting in decreased proliferation and colony formation, and increased DNA damage compared to isogenic cells with wild-type STAG2 (PMID: 24356817).",
            "molecularProfile": {
                "id": 22904,
                "profileName": "STAG2 N357fs"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5470,
                    "pubMedId": 21852505,
                    "title": "Mutational inactivation of STAG2 causes aneuploidy in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21852505"
                },
                {
                    "id": 5471,
                    "pubMedId": 24356817,
                    "title": "Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24356817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6214,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to treatment with Veliparib (ABT-888) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817).",
            "molecularProfile": {
                "id": 22904,
                "profileName": "STAG2 N357fs"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5470,
                    "pubMedId": 21852505,
                    "title": "Mutational inactivation of STAG2 causes aneuploidy in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21852505"
                },
                {
                    "id": 5471,
                    "pubMedId": 24356817,
                    "title": "Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24356817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6215,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505), demonstrated increased sensitivity to treatment with Rubraca (rucaparib) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817).",
            "molecularProfile": {
                "id": 22904,
                "profileName": "STAG2 N357fs"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5470,
                    "pubMedId": 21852505,
                    "title": "Mutational inactivation of STAG2 causes aneuploidy in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21852505"
                },
                {
                    "id": 5471,
                    "pubMedId": 24356817,
                    "title": "Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24356817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6216,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 S653*, PMID: 21852505) demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817).",
            "molecularProfile": {
                "id": 22907,
                "profileName": "STAG2 S653*"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5470,
                    "pubMedId": 21852505,
                    "title": "Mutational inactivation of STAG2 causes aneuploidy in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21852505"
                },
                {
                    "id": 5471,
                    "pubMedId": 24356817,
                    "title": "Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24356817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6218,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and Temodar (temozolomide) compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817).",
            "molecularProfile": {
                "id": 22904,
                "profileName": "STAG2 N357fs"
            },
            "therapy": {
                "id": 1438,
                "therapyName": "Olaparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5470,
                    "pubMedId": 21852505,
                    "title": "Mutational inactivation of STAG2 causes aneuploidy in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21852505"
                },
                {
                    "id": 5471,
                    "pubMedId": 24356817,
                    "title": "Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24356817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6219,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and camptothecin compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817).",
            "molecularProfile": {
                "id": 22904,
                "profileName": "STAG2 N357fs"
            },
            "therapy": {
                "id": 4095,
                "therapyName": "Camptothecin + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5470,
                    "pubMedId": 21852505,
                    "title": "Mutational inactivation of STAG2 causes aneuploidy in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21852505"
                },
                {
                    "id": 5471,
                    "pubMedId": 24356817,
                    "title": "Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24356817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6220,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 S653*, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and camptothecin compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817).",
            "molecularProfile": {
                "id": 22907,
                "profileName": "STAG2 S653*"
            },
            "therapy": {
                "id": 3397,
                "therapyName": "Camptothecin",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5470,
                    "pubMedId": 21852505,
                    "title": "Mutational inactivation of STAG2 causes aneuploidy in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21852505"
                },
                {
                    "id": 5471,
                    "pubMedId": 24356817,
                    "title": "Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24356817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6317,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XL147 inhibited tumor growth in xenograft models of a human glioblastoma cell line harboring PTEN V54fs (PMID: 25637314).",
            "molecularProfile": {
                "id": 23098,
                "profileName": "PTEN V54fs"
            },
            "therapy": {
                "id": 1050,
                "therapyName": "XL147",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5522,
                    "pubMedId": 25637314,
                    "title": "The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25637314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6413,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a pooled analysis of several clinical trials, use of Valproic acid was not associated with improved progression-free survival or overall survival in glioblastoma patients (PMID: 26786929).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1076,
                "therapyName": "Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5568,
                    "pubMedId": 26786929,
                    "title": "Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26786929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6705,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Ad-RTS-IL-12 plus AL demonstrated safety and preliminary efficacy in glioblastoma multiforme patients, with 100% (7/7) of patients remained alive and 5 patients having a follow-up of more than 90 days posttreatment (J Clin Oncol 34, 2016 (suppl; abstr 2052)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4250,
                "therapyName": "Ad-RTS-IL-12 plus AL",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5754,
                    "pubMedId": null,
                    "title": "Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_168752.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6717,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Selinexor (KPT-330) treatment resulted in partial response in 11% (3/27) and stable disease in 22% (6/27) of patients with glioblastoma multiforme (J Clin Oncol 34, 2016 (suppl; abstr 2077)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1749,
                "therapyName": "Selinexor",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5777,
                    "pubMedId": null,
                    "title": "A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).",
                    "url": "http://abstracts.asco.org/176/AbstView_176_170208.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6981,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-414 induced cytoxicity in a glioblastoma cell line harboring amplified EGFR vIII (exon 2-7 deletion) in culture, and induced complete tumor regression in cell line xenograft models of glioblastoma harboring amplified EGFR vIII (PMID: 26846818).",
            "molecularProfile": {
                "id": 24170,
                "profileName": "EGFR act mut EGFR amp"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5960,
                    "pubMedId": 26846818,
                    "title": "ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6991,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-414 induced tumor regression in a patient-derived xenograft model of glioblastoma multiforme harboring amplified wild-type EGFR and EGFR vIII (exon 2-7 deletion) (PMID: 26846818).",
            "molecularProfile": {
                "id": 24172,
                "profileName": "EGFR act mut EGFR amp EGFR wild-type"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5960,
                    "pubMedId": 26846818,
                    "title": "ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6994,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-414 in combination with Temodar (temozolomide) and radiotherapy inhibited tumor growth and resulted in tumor growth delay in a glioblastoma multiforme cell line xenograft model harboring amplified EGFR vIII (exon 2-7 deletion), with increased efficacy compared to the combination of Temodar (temozolomide) and radiotherapy (PMID: 26846818).",
            "molecularProfile": {
                "id": 24170,
                "profileName": "EGFR act mut EGFR amp"
            },
            "therapy": {
                "id": 4346,
                "therapyName": "Depatuxizumab mafodotin + Radiotherapy + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5960,
                    "pubMedId": 26846818,
                    "title": "ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7039,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and viability of several Met over expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 1656,
                "therapyName": "Altiratinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6048,
                    "pubMedId": 26965451,
                    "title": "Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26965451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7040,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Altiratinib (DCC-2701) and Avastin (bevacizumab) inhibited tumor growth and invasiveness, decreased blood vessel formation, and prolonged survival in cell line xenograft models of MET-expressing glioblastoma (PMID: 26965451).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 4353,
                "therapyName": "Altiratinib + Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6048,
                    "pubMedId": 26965451,
                    "title": "Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26965451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7041,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Altiratinib (DCC-2701) inhibited viability of several MET-expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 1656,
                "therapyName": "Altiratinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6048,
                    "pubMedId": 26965451,
                    "title": "Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26965451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7043,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Adavosertib (MK-1775) decreased CDK1 phosphorylation and reduced tumor growth in patient-derived xenograft models of glioblastoma multiforme that harbor TP53 mutations (PMID: 27196784).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6050,
                    "pubMedId": 27196784,
                    "title": "Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196784"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7138,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of glioblastoma (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",
            "molecularProfile": {
                "id": 5943,
                "profileName": "NOTCH1 positive"
            },
            "therapy": {
                "id": 2958,
                "therapyName": "LY3039478",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3325,
                    "pubMedId": null,
                    "title": "Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/1131.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7272,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Si306 inhibited SRC phosphorylation and proliferation of SRC-expressing glioblastoma cell lines in culture, and inhibited tumor growth and increased survival in cell line xenograft models (PMID: 27196762).",
            "molecularProfile": {
                "id": 1875,
                "profileName": "SRC positive"
            },
            "therapy": {
                "id": 4430,
                "therapyName": "Si306",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6269,
                    "pubMedId": 27196762,
                    "title": "Suppression of SRC Signaling Is Effective in Reducing Synergy between Glioblastoma and Stromal Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7273,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Si306 in combination with radiotherapy decreased growth of radiotherapy-sensitive SRC-positive glioblastoma cells in culture and decreased tumor growth in cell line xenograft models, with increased efficacy compared to Si306 or radiotherapy alone (PMID: 27196762).",
            "molecularProfile": {
                "id": 1875,
                "profileName": "SRC positive"
            },
            "therapy": {
                "id": 4431,
                "therapyName": "Radiotherapy + Si306",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6269,
                    "pubMedId": 27196762,
                    "title": "Suppression of SRC Signaling Is Effective in Reducing Synergy between Glioblastoma and Stromal Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7432,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, three patients with glioblastoma demonstrated stable disease when treated with Abemaciclib (LY2835219) (PMID: 27217383).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6356,
                    "pubMedId": 27217383,
                    "title": "Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217383"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7534,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A66 did not inhibit tumor growth in a PTEN-null cell line xenograft model of glioblastoma (PMID: 21668414).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 617,
                "therapyName": "A66",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 223,
                    "pubMedId": 21668414,
                    "title": "A drug targeting only p110\u03b1 can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21668414"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7536,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Dovitinib (TKI258) treatment resulted in a progression free survival rate at 6 months of 16.7% (2/12) in patients with recurrent glioblastoma (PMID: 27100354).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6402,
                    "pubMedId": 27100354,
                    "title": "Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27100354"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7556,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with recurrent glioblastoma treated with Cediranib (AZD-2171), in combination with Lomustine (CCNU), demonstrated 50% tumor regression at 6 weeks, complete response at 24 weeks, and achieved clinical remission for over 6 years (PMID: 26929887).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4515,
                "therapyName": "Cediranib + Lomustine",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6418,
                    "pubMedId": 26929887,
                    "title": "Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26929887"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7588,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with the combination of Cediranib (AZD-2171) and Iressa (gefitinib) resulted in a trend toward improved progression-free survival compared to Cediranib (AZD-2171) and placebo (3.6 months vs 2.8 months), and resulted in a response rate of 42% (8/19), compared to 26% (5/19) with Cediranib (AZD-2171) plus placebo in patients with recurrent glioblastoma (PMID: 27232884).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3229,
                "therapyName": "Cediranib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6438,
                    "pubMedId": 27232884,
                    "title": "Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27232884"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8043,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) inhibited Egfr signaling and survival of patient-derived EGFR amplified glioblastoma cells in culture and in intracranial xenograft models (PMID: 25939761).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6540,
                    "pubMedId": 25939761,
                    "title": "Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939761"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8044,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) did not inhibit Egfr signaling or survival of patient-derived EGFR wild-type glioblastoma cells in culture and in intracranial xenograft models (PMID: 25939761).",
            "molecularProfile": {
                "id": 343,
                "profileName": "EGFR wild-type"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6540,
                    "pubMedId": 25939761,
                    "title": "Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939761"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8045,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived EGFR amplified glioblastoma cells harboring PTEN loss demonstrated reduced sensitivity to Vizimpro (dacomitinib) induced growth inhibition in culture and in xenograft models (PMID: 25939761).",
            "molecularProfile": {
                "id": 26141,
                "profileName": "EGFR amp PTEN loss"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6540,
                    "pubMedId": 25939761,
                    "title": "Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939761"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8213,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ST-11 induced cell-cycle arrest and apoptosis in glioblastoma cell lines in culture, and reduced tumor burden in mouse models of glioblastoma (PMID: 27325686).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4663,
                "therapyName": "ST-11",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6571,
                    "pubMedId": 27325686,
                    "title": "ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325686"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8275,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-562271 inhibited PTK2 signaling, resulted in apoptosis and tumor suppression in glioblastoma cancer cell line xenograft models (PMID: 18339875).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 2087,
                "therapyName": "PF-562271",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1919,
                    "pubMedId": 18339875,
                    "title": "Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18339875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8572,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited cell survival of a human glioblastoma multiforme cell line harboring an EGFR-SEPT14 fusion, and inhibited tumor growth in xenograft models (PMID: 23917401).",
            "molecularProfile": {
                "id": 26359,
                "profileName": "EGFR - SEPTIN14"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3963,
                    "pubMedId": 23917401,
                    "title": "The integrated landscape of driver genomic alterations in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23917401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8573,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) inhibited cell survival of a human glioblastoma multiforme cell line harboring an EGFR-SEPT14 fusion, and inhibited tumor growth in xenograft models (PMID: 23917401).",
            "molecularProfile": {
                "id": 26359,
                "profileName": "EGFR - SEPTIN14"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3963,
                    "pubMedId": 23917401,
                    "title": "The integrated landscape of driver genomic alterations in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23917401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8579,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, long term treatment with BLZ945 resulted in resistance in 56% of transgenic glioblastoma multiforme mouse models (PMID: 27199435).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2844,
                "therapyName": "BLZ945",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6692,
                    "pubMedId": 27199435,
                    "title": "The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27199435"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8583,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and BLZ945 compared to BLZ945 alone resulted in enhanced survival and tumor regression in transgenic mouse models of glioblastoma (PMID: 27199435).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4772,
                "therapyName": "BLZ945 + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6692,
                    "pubMedId": 27199435,
                    "title": "The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27199435"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8586,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BKM120 demonstrated a survival similar to vehicle in transgenic mouse models of glioblastoma and therefore, resulted in no benefit (PMID: 27199435).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6692,
                    "pubMedId": 27199435,
                    "title": "The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27199435"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8587,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLZ945 resulted in limited benefit in transgenic mouse models of glioblastoma harboring a loss of PTEN (PMID: 27199435).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 2844,
                "therapyName": "BLZ945",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6692,
                    "pubMedId": 27199435,
                    "title": "The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27199435"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8588,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BLZ945 demonstrated some efficacy, specifically a 56% tumor reduction, in transgenic mouse models of glioblastoma with a loss of TP53 (PMID: 27199435).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 2844,
                "therapyName": "BLZ945",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6692,
                    "pubMedId": 27199435,
                    "title": "The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27199435"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8591,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Linsitinib (OSI-906) and BLZ945 compared to BLZ945 alone resulted in a greater survival benefit, decreased cell proliferation, and tumor regression in transgenic mouse models of glioblastoma expressing IGF1R (PMID: 27199435).",
            "molecularProfile": {
                "id": 16581,
                "profileName": "IGF1R positive"
            },
            "therapy": {
                "id": 4773,
                "therapyName": "BLZ945 + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6692,
                    "pubMedId": 27199435,
                    "title": "The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27199435"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8593,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma transgenic mouse models expressing IGF1R demonstrated minimal survival when treated with Linsitinib (OSI-906) alone (PMID: 27199435).",
            "molecularProfile": {
                "id": 16581,
                "profileName": "IGF1R positive"
            },
            "therapy": {
                "id": 798,
                "therapyName": "Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6692,
                    "pubMedId": 27199435,
                    "title": "The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27199435"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8595,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLZ945 treatment resulted in minimal survival of transgenic glioblastoma mouse models expressing IGF1R (PMID: 27199435).",
            "molecularProfile": {
                "id": 16581,
                "profileName": "IGF1R positive"
            },
            "therapy": {
                "id": 2844,
                "therapyName": "BLZ945",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6692,
                    "pubMedId": 27199435,
                    "title": "The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27199435"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8710,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited growth of a HGF-driven glioblastoma cell line with wild-type MET in culture and inhibited tumor growth in xenograft models (PMID: 27550450).",
            "molecularProfile": {
                "id": 26414,
                "profileName": "HGF pos MET wild-type"
            },
            "therapy": {
                "id": 4799,
                "therapyName": "KTN0073-IgG2",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6713,
                    "pubMedId": 27550450,
                    "title": "Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8728,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, addition of RO4929097 to Temodar (temozolomide) and radiation therapy inhibited Notch signaling and cell proliferation in patient tumor samples, resulted in a median overall survival of 21 months and a median progression free survival of 13 months in glioblastoma patients (PMID: 27154916).",
            "molecularProfile": {
                "id": 5943,
                "profileName": "NOTCH1 positive"
            },
            "therapy": {
                "id": 4803,
                "therapyName": "Radiotherapy + RO4929097 + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6719,
                    "pubMedId": 27154916,
                    "title": "Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27154916"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8769,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Torisel (temsirolimus) and radiotherapy did not result in an improved overall survival or progression free survival when compared to the combination of Temodar (temozolomide) and radiotherapy in glioblastoma patients with an unmethylated MGMT promoter (PMID: 27143690).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4808,
                "therapyName": "Radiotherapy + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6737,
                    "pubMedId": 27143690,
                    "title": "Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27143690"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8939,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3023414 inhibited Pi3k/mTor signaling and proliferation in PTEN deficient glioblastoma cells in culture, and resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 1069,
                "therapyName": "LY3023414",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6792,
                    "pubMedId": 27439478,
                    "title": "Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27439478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8963,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MGCD516 decreased tumor cell proliferation, tumor vascularization, and target phosphorylation in human glioblastoma multiforme cell line xenograft models (Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1, Abstract 930).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1655,
                "therapyName": "MGCD516",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6811,
                    "pubMedId": null,
                    "title": "Preclinical characterization of MG516, a novel inhibitor of receptor tyrosine kinases involved in resistance to targeted therapies.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/930"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9112,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BAL101553 improved survival and decreased tumor growth and invasion in glioblastoma cell line xenograft models with high MAPRE1 (EB1) expression (PMID: 27540016).",
            "molecularProfile": {
                "id": 26743,
                "profileName": "MAPRE1 positive"
            },
            "therapy": {
                "id": 4908,
                "therapyName": "BAL101553",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6923,
                    "pubMedId": 27540016,
                    "title": "The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27540016"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9312,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma multiforme (GBM) cell lines with amplification of MDM2 and wild-type TP53 demonstrated sensitivity to RG7112 in culture, resulting in decreased viability and restoration of Tp53 signaling, and treatment with RG7112 resulted in growth inhibition in MDM2-amplified TP53 wild-type GBM cell line xenograft models (PMID: 26482041).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 2076,
                "therapyName": "RG7112",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7072,
                    "pubMedId": 26482041,
                    "title": "Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26482041"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9313,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human glioblastoma multiforme cell lines with gain or amplification of MDM4 and wild-type TP53 demonstrated sensitivity to RG7112 in culture, resulting in decreased cell viability (PMID: 26482041).",
            "molecularProfile": {
                "id": 26818,
                "profileName": "MDM4 amp TP53 wild-type"
            },
            "therapy": {
                "id": 2076,
                "therapyName": "RG7112",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7072,
                    "pubMedId": 26482041,
                    "title": "Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26482041"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9353,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited proliferation of RB1-proficient glioblastoma cell lines in culture and inhibited tumor growth in intracranial cell line xenograft models (PMID: 20354191).",
            "molecularProfile": {
                "id": 2395,
                "profileName": "RB1 positive"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4520,
                    "pubMedId": 20354191,
                    "title": "Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20354191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9354,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) failed to inhibit growth of RB1-deficient glioblastoma cell lines in culture and in intracranial cell line xenograft models (PMID: 20354191).",
            "molecularProfile": {
                "id": 5891,
                "profileName": "RB1 inact mut"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4520,
                    "pubMedId": 20354191,
                    "title": "Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20354191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9355,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited tumor growth and improved survival in patient-derived intracranial xenografts models of RB-proficient glioblastoma harboring homozygous deletion of the CDKN2A and CDKN2B (PMID: 20354191).",
            "molecularProfile": {
                "id": 26829,
                "profileName": "CDKN2A loss CDKN2B loss RB1 pos"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4520,
                    "pubMedId": 20354191,
                    "title": "Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20354191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9359,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Keytruda (pembrolizumab) treatment resulted in partial response in 4% (1/25), stable disease in 48% (12/25), a median progression free survival of 2.8 months, and a median overall survival of 14.4 months in patients with CD274 (PD-L1) positive, bevacizumab-naive recurrent glioblastoma (Neuro Oncol (2016) 18 (suppl 6): vi25-vi26.).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 7124,
                    "pubMedId": null,
                    "title": "RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM)",
                    "url": "http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi25.4.abstract?sid=af283a96-f950-4f1d-a7cb-611b9ddd3325"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16074,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, response to Keytruda (pembrolizumab) or Opdivo (nivolumab) therapy was not predicted by RNA expression levels of CD274 (PD-L1) in glioblastoma patients (PMID: 30742119).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9360,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Imfinzi (durvalumab) treatment resulted in partial response in 16.7% (5/30), stable disease in 43.3% (13/30), and an estimated 6 month progression free survival of 20.0% in patients with Bevacizumab-naive, recurrent glioblastoma (Neuro Oncol (2016) 18 (suppl 6): vi18.).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1356,
                "therapyName": "Durvalumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7125,
                    "pubMedId": null,
                    "title": "PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH GLIOBLASTOMA (GBM): RESULTS FOR COHORT B (DUR MONOTHERAPY), BEVACIZUMAB (BEV) NA\u00cfVE PATIENTS WITH RECURRENT GBM",
                    "url": "http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi18.1.abstract?sid=fff79e74-73b2-44b6-a1ee-800e65801125"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9363,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived glioblastoma cell lines harboring CDK4 amplification and expressing Cdkn2a were resistant to Ibrance (palbociclib) in culture (PMID: 22711607).",
            "molecularProfile": {
                "id": 26832,
                "profileName": "CDK4 amp CDKN2A pos"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3561,
                    "pubMedId": 22711607,
                    "title": "p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22711607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9364,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived glioblastoma cells harboring RB1 truncation mutation and expressing Cdkn2a were resistant to Ibrance (palbociclib) in culture (PMID: 22711607).",
            "molecularProfile": {
                "id": 26833,
                "profileName": "CDKN2A pos RB1 inact mut"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3561,
                    "pubMedId": 22711607,
                    "title": "p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22711607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9365,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited proliferation of patient-derived glioblastoma cells harboring homozygous deletion of CDKN2A and hemizygous deletion of CDK4 in culture (PMID: 22711607).",
            "molecularProfile": {
                "id": 26837,
                "profileName": "CDK4 pos CDKN2C del"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3561,
                    "pubMedId": 22711607,
                    "title": "p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22711607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9366,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited proliferation of patient-derived glioblastoma cells harboring homozygous deletion of CDKN2A and CDK6 amplification in culture (PMID: 22711607).",
            "molecularProfile": {
                "id": 26838,
                "profileName": "CDK6 amp CDKN2A del"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3561,
                    "pubMedId": 22711607,
                    "title": "p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22711607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9368,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited proliferation of patient-derived glioblastoma cells harboring homozygous deletion of CDKN2A in culture and prolonged survival in patient-derived xenograft models (PMID: 22711607).",
            "molecularProfile": {
                "id": 6542,
                "profileName": "CDKN2A del"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3561,
                    "pubMedId": 22711607,
                    "title": "p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22711607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14306,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, SL-701 treatment resulted in partial response in 2.2% (1/46) and stable disease in 32.6% (15/46) of patients with relapsed/refractory glioblastoma, with a 12-month overall survival rate of 37% (median 11 months) (J Clin Oncol 36, 2018 (suppl; abstr 2058); NCT02078648).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3010,
                "therapyName": "SL-701",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11581,
                    "pubMedId": null,
                    "title": "Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.",
                    "url": "http://abstracts.asco.org/214/AbstView_214_229695.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9471,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, SL-701 treatment resulted in partial response in 3.3% (1/30) and stable disease in 50% (15/30) of patients with recurrant glioblastoma multiforme (Neuro Oncol (2016) 18 (suppl 6): vi20.).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3010,
                "therapyName": "SL-701",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7199,
                    "pubMedId": null,
                    "title": "PHASE 2 TRIAL OF SL-701, A NOVEL IMMUNOTHERAPY COMPRISED OF SYNTHETIC SHORT PEPTIDES AGAINST GBM TARGETS IL-13R?2, EphA2, AND SURVIVIN, IN ADULTS WITH SECOND-LINE RECURRENT GBM: INTERIM RESULTS",
                    "url": "http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi20.1.abstract?sid=70edd8a6-f8e7-47d1-927b-032ac6c0b974"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14308,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, SL-701 and Avastin (bevacizumab) combination treatment resulted in complete response in 7.1% (2/28), partial response in 14.3% (4/28) and stable disease in 67.9.6% (19/28) of patients with relapsed/refractory glioblastoma, with a 12-month overall survival rate of 43% (median 11.7 months) (J Clin Oncol 36, 2018 (suppl; abstr 2058); NCT02078648).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5025,
                "therapyName": "Bevacizumab + SL-701",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11581,
                    "pubMedId": null,
                    "title": "Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.",
                    "url": "http://abstracts.asco.org/214/AbstView_214_229695.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9472,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, SL-701 and Avastin (bevacizumab) combination treatment resulted in partial response in 25% (1/4) and stable disease in 75% (3/4) of patients with recurrant glioblastoma multiforme (Neuro Oncol (2016) 18 (suppl 6): vi20.).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5025,
                "therapyName": "Bevacizumab + SL-701",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7199,
                    "pubMedId": null,
                    "title": "PHASE 2 TRIAL OF SL-701, A NOVEL IMMUNOTHERAPY COMPRISED OF SYNTHETIC SHORT PEPTIDES AGAINST GBM TARGETS IL-13R?2, EphA2, AND SURVIVIN, IN ADULTS WITH SECOND-LINE RECURRENT GBM: INTERIM RESULTS",
                    "url": "http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi20.1.abstract?sid=70edd8a6-f8e7-47d1-927b-032ac6c0b974"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9484,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Pexidartinib (PLX3397) in combination with radiation therapy and Temodar (temozolomide) demonstrated safety and improved efficacy over standard therapy, resulting in a median progression-free survival of 9.7 months and an estimated overall survival of 25.1 months in newly diagnosed glioblastoma multiforme patients (Neuro Oncol (2016) 18 (suppl 6): vi6).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7203,
                    "pubMedId": null,
                    "title": "INITIAL RESULTS OF PLX108-08: AN OPEN LABEL PHASE 1B/2 STUDY OF ORALLY ADMINISTERED PEXIDARTINIB (PLX3397) IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA",
                    "url": "http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi6.1.abstract?sid=4bb3de14-d380-4d46-a482-fff2514faa51"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9684,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E-4031 decreased proliferation of patient-derived glioblastoma cells expressing high levels of KCNH2 (HERG) in culture (PMID: 27635088).",
            "molecularProfile": {
                "id": 26976,
                "profileName": "KCNH2 over exp"
            },
            "therapy": {
                "id": 5159,
                "therapyName": "E-4031",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7480,
                    "pubMedId": 27635088,
                    "title": "Administration of Non-Torsadogenic human Ether-\u00e0-go-go-Related Gene Inhibitors Is Associated with Better Survival for High hERG-Expressing Glioblastoma Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27635088"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9685,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with PDZ1i in glioma cell line xenograft models expressing SDCBP resulted in increased survival of the mice and decreased tumor invasion when compared to a control treatment (PMID: 28011764).",
            "molecularProfile": {
                "id": 26974,
                "profileName": "SDCBP positive"
            },
            "therapy": {
                "id": 5160,
                "therapyName": "PDZ1i",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7482,
                    "pubMedId": 28011764,
                    "title": "Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28011764"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9686,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PDZ1i to radiotherapy resulted in enhanced sensitivity and a greater decrease in cell invasion compared to radiotherapy alone when treating glioblastoma xenograft models expressing SDCBP (PMID: 28011764).",
            "molecularProfile": {
                "id": 26974,
                "profileName": "SDCBP positive"
            },
            "therapy": {
                "id": 5161,
                "therapyName": "PDZ1i + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7482,
                    "pubMedId": 28011764,
                    "title": "Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28011764"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9778,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including a partial response in a glioblastoma multiforme patient harboring KIT and PDGFRA amplification (EORTC-NCI-AACR 2016, Abs 7LBA).",
            "molecularProfile": {
                "id": 27080,
                "profileName": "KIT amp PDGFRA amp"
            },
            "therapy": {
                "id": 4316,
                "therapyName": "Ripretinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7598,
                    "pubMedId": null,
                    "title": "DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study",
                    "url": "http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9825,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ONC201 (TIC10) and Navitoclax (ABT-263) increased apoptosis and worked synergistically to inhibit proliferation of a glioblastoma cell line harboring mutations in PTEN and TP53 in culture (PMID: 26474387).",
            "molecularProfile": {
                "id": 5387,
                "profileName": "PTEN mut TP53 mut"
            },
            "therapy": {
                "id": 5245,
                "therapyName": "Navitoclax + ONC201",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7647,
                    "pubMedId": 26474387,
                    "title": "TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26474387"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10064,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Altiratinib (DCC-701) increased survival in a MET and HGF-expressing glioblastoma cell line xenograft model (PMID: 26285778).",
            "molecularProfile": {
                "id": 27233,
                "profileName": "HGF pos MET pos"
            },
            "therapy": {
                "id": 1656,
                "therapyName": "Altiratinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10065,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Altiratinib (DCC-701) and Avastin (bevacizumab) resulted in decreased tumor growth, increased survival, and a decrease in TIE2-expressing circulating monocytes in a MET and HGF-expressing glioblastoma cell line xenograft model (PMID: 26285778).",
            "molecularProfile": {
                "id": 27233,
                "profileName": "HGF pos MET pos"
            },
            "therapy": {
                "id": 4353,
                "therapyName": "Altiratinib + Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10191,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PD-0325901, demonstrating increased viability of CD133 positive cells in culture (PMID: 26573800).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 8161,
                    "pubMedId": 26573800,
                    "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10192,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PLX4720, demonstrating increased viability of CD133 positive cells in culture and in xenograft models (PMID: 26573800).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 8161,
                    "pubMedId": 26573800,
                    "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10193,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line treated with BI2536 demonstrated decreased cell viability in culture (PMID: 26573800).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 676,
                "therapyName": "BI2536",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8161,
                    "pubMedId": 26573800,
                    "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10194,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated sensitivity to BI2536 in culture (PMID: 26573800).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 676,
                "therapyName": "BI2536",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8161,
                    "pubMedId": 26573800,
                    "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10195,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BI 2536 and PD-0325901 resulted in greater inhibition of cell proliferation in glioblastoma cells in culture compared to treatment with either agent alone (PMID: 26573800).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5423,
                "therapyName": "BI2536 + PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8161,
                    "pubMedId": 26573800,
                    "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10196,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BI 2536 and PLX4720 resulted in suppression of downstream signaling, increased apoptotic activity, inhibition of cell proliferation, and tumor growth suppression in glioblastoma cell line xenograft models harboring BRAF V600E (PMID: 26573800).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 5422,
                "therapyName": "BI2536 + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8161,
                    "pubMedId": 26573800,
                    "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10266,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-777607 inhibited Axl phosphorylation, resulted in decreased viability of glioblastoma multiforme cell lines in culture and in cell line xenograft models (PMID: 26848524).",
            "molecularProfile": {
                "id": 20482,
                "profileName": "AXL positive"
            },
            "therapy": {
                "id": 687,
                "therapyName": "BMS-777607",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8239,
                    "pubMedId": 26848524,
                    "title": "Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26848524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10339,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GDC-0152 increased apoptosis of glioblastoma multiforme (GBM) cell lines in culture, and resulted in increased tumor cell differentiation and apoptosis, increased survival, and decreased tumor growth in GBM cell line xenograft models (PMID: 27490930).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5475,
                "therapyName": "GDC-0152",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8319,
                    "pubMedId": 27490930,
                    "title": "Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27490930"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10479,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PRX177561 and Sutent (sunitinib) decreased tumor growth and improved time-to-progression, disease-free survival, and overall survival over either agent alone in glioblastoma cell line xenograft models (PMID: 28057017).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5529,
                "therapyName": "PRX177561 + Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8533,
                    "pubMedId": 28057017,
                    "title": "The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28057017"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10480,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PRX177561 and Avastin (bevacizumab) decreased tumor growth and improved time-to-progression, disease-free survival, and overall survival over either agent alone in glioblastoma cell line xenograft models (PMID: 28057017).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5528,
                "therapyName": "Bevacizumab + PRX177561",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8533,
                    "pubMedId": 28057017,
                    "title": "The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28057017"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10643,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, two PTEN-deficient glioblastoma cell line xenograft models were sensitive to GDC-0084 treatment, resulting in decreased tumor volumes by 70% and 40%, and inhibition of PI3K pathway signaling (PMID: 27638506).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 2018,
                "therapyName": "GDC-0084",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8698,
                    "pubMedId": 27638506,
                    "title": "Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27638506"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10704,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring a PTEN inactivating mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).",
            "molecularProfile": {
                "id": 2095,
                "profileName": "PTEN inact mut"
            },
            "therapy": {
                "id": 1051,
                "therapyName": "SAR245409",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8768,
                    "pubMedId": 24634413,
                    "title": "Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24634413"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10709,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring a PTEN inactivating mutation (PMID: 24634413) was sensitive to SF1126, demonstrating inhibition of tumor growth in cell line xenograft models (PMID: 18172313).",
            "molecularProfile": {
                "id": 2095,
                "profileName": "PTEN inact mut"
            },
            "therapy": {
                "id": 915,
                "therapyName": "SF1126",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8768,
                    "pubMedId": 24634413,
                    "title": "Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24634413"
                },
                {
                    "id": 8775,
                    "pubMedId": 18172313,
                    "title": "A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18172313"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10740,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels in a glioblastoma cell line expressing IDH2 R140Q in culture and in xenograft models (PMID: 28193778).",
            "molecularProfile": {
                "id": 1254,
                "profileName": "IDH2 R140Q"
            },
            "therapy": {
                "id": 2982,
                "therapyName": "Enasidenib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8791,
                    "pubMedId": 28193778,
                    "title": "AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28193778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10741,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels in a glioblastoma cell line expressing IDH2 R172K in culture (PMID: 28193778).",
            "molecularProfile": {
                "id": 1255,
                "profileName": "IDH2 R172K"
            },
            "therapy": {
                "id": 2982,
                "therapyName": "Enasidenib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8791,
                    "pubMedId": 28193778,
                    "title": "AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28193778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10827,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alisertib (MLN8237) decreased proliferation of primary glioblastoma cell lines in culture, and improved survival of primary glioblastoma cell line xenograft models, including models resistant to Avastin (bevacizumab) (PMID: 27816996).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8857,
                    "pubMedId": 27816996,
                    "title": "Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27816996"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10859,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived glioblastoma cells harboring MYC amplification demonstrated decreased cell viability and cell proliferation, and increased apoptotic activity when treated with FK866 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 5662,
                "therapyName": "FK866",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10860,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived glioblastoma cells harboring MYC amplification demonstrated decreased cell viability and cell proliferation, and increased apoptotic activity when treated with GMX1778 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 5666,
                "therapyName": "GMX1778",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10861,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived glioblastoma cells harboring MYCN amplification demonstrated decreased cell viability and cell proliferation, and increased apoptotic activity when treated with FK866 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 5662,
                "therapyName": "FK866",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10862,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived glioblastoma cells harboring MYCN amplification demonstrated decreased cell viability and cell proliferation, and increased apoptotic activity when treated with GMX1778 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 5666,
                "therapyName": "GMX1778",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10863,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells over expressing MYC demonstrated decreased cell viability when treated with FK866 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 5662,
                "therapyName": "FK866",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10864,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells over expressing MYC demonstrated decreased cell viability when treated with GMX1778 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 5666,
                "therapyName": "GMX1778",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11014,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SA16 treatment in glioblastoma cells resulted in decreased cell proliferation, reduced cell viability, and apoptotic induction in culture, and inhibited glioma stem cell formation (PMID: 27797168).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5775,
                "therapyName": "SA16",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8978,
                    "pubMedId": 27797168,
                    "title": "Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797168"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11015,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MP7 treatment did not result in significant inhibition of cell proliferation and showed minimal change in cell viability in a glioblastoma cell line in culture, thus, providing no benefit (PMID: 27797168).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5769,
                "therapyName": "MP7",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8978,
                    "pubMedId": 27797168,
                    "title": "Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797168"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11016,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of MP7 and Alisertib (MLN8237) resulted in an additive effect in glioblastoma cells in culture, demonstrating an increase in antiproliferative activity, decreased cell viability, and inhibition of glioma stem cell colony formation (PMID: 27797168).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5776,
                "therapyName": "Alisertib + MP7",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8978,
                    "pubMedId": 27797168,
                    "title": "Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797168"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11559,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the mitochondrial Hsp90 inhibitor G-TPP and the broad BH3 mimetic Navitoclax (ABT-263) synergistically inhibited viability of established lines and patient-derived glioblastoma cells in culture, and inhibited tumor growth in cell line and patient-derived xenograft models (PMID: 28522750).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6064,
                "therapyName": "G-TPP + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9648,
                    "pubMedId": 28522750,
                    "title": "Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11561,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the mitochondrial Hsp90 inhibitor G-TPP and the broad BH3 mimetic Obatoclax (GX015-070) synergistically inhibited viability of established lines and patient-derived glioblastoma cells in culture (PMID: 28522750).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6065,
                "therapyName": "G-TPP + Obatoclax",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9648,
                    "pubMedId": 28522750,
                    "title": "Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11562,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the mitochondrial Hsp90 inhibitor G-TPP and the Bcl-xL inhibitor WEHI-539 synergistically inhibited viability of established lines and patient-derived glioblastoma cells in culture (PMID: 28522750).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6066,
                "therapyName": "G-TPP + WEHI-539",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9648,
                    "pubMedId": 28522750,
                    "title": "Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11563,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the mitochondrial Hsp90 inhibitor G-TPP and the Bcl2 inhibitor Venclexta (venetoclax) synergistically inhibited viability of established lines and patient-derived glioblastoma cells in culture (PMID: 28522750).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6067,
                "therapyName": "G-TPP + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9648,
                    "pubMedId": 28522750,
                    "title": "Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11564,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the mitochondrial Hsp90 inhibitor G-TPP and the Mcl-1 inhibitor A-1210477 synergistically inhibited viability of established lines and patient-derived glioblastoma cells in culture (PMID: 28522750).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6068,
                "therapyName": "A-1210477 + G-TPP",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9648,
                    "pubMedId": 28522750,
                    "title": "Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11716,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, glioblastoma patients positive for ERBB2 (HER2) demonstrated antitumor activity when treated with ERBB2 (HER2)-CAR-T cell therapy including one patient with a partial response and seven patients with stable disease ranging from 8 weeks to 29 months (PMID: 28426845).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 6007,
                "therapyName": "HER2 CAR-T cells",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9733,
                    "pubMedId": 28426845,
                    "title": "HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28426845"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12698,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (Ulixertinib) resulted in a partial response in a patient with glioblastoma harboring BRAF V600E (PMID: 29247021).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10607,
                    "pubMedId": 29247021,
                    "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12767,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of A-966492 and Hycamtin (topotecan) resulted in enhanced radiosensitivity in glioblastoma cells in culture, demonstrating a greater reduction in cell survival (PMID: 28797568).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6642,
                "therapyName": "A-966492 + Radiotherapy + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10705,
                    "pubMedId": 28797568,
                    "title": "The combination of A-966492 and Topotecan for effective radiosensitization on glioblastoma spheroids.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28797568"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12787,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SR9009 inhibited growth of glioblastoma cell lines in culture, resulted in apoptosis in tumors and prolonged survival in both cell line and patient-derived xenograft models (PMID: 29320480).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6650,
                "therapyName": "SR9009",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10714,
                    "pubMedId": 29320480,
                    "title": "Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320480"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13064,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of BGB-5777, anti-PD-1 antibody, and whole brain radiation resulted in significantly improved survival compared to control antibody in mouse models of glioblastoma multiforme, regardless of the Ido1 expression level (Neuro-Oncology, Volume 19, Issue suppl_6, 6 November 2017, Pages vi117).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6748,
                "therapyName": "BGB-5777",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10944,
                    "pubMedId": null,
                    "title": "COMBINATION IMMUNOTHERAPY WITH IDO1 INHIBITION ENHANCES TREATMENT EFFICACY IN MULTIPLE MODELS OF GLIOBLASTOMA MODEL",
                    "url": "https://academic.oup.com/neuro-oncology/article-abstract/19/suppl_6/vi117/4590584?redirectedFrom=fulltext"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13400,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "IDH2 mutations aid in the diagnosis of secondary grade IV glioblastomas (NCCN.org).",
            "molecularProfile": {
                "id": 5912,
                "profileName": "IDH2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13498,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SLC-0111, in combination with Telmozolomide, decreased cell proliferation of GBM cultured cells overexpressing Ca9 and increased survival of GBM patient-derived xenograft (PDX) models (PMID: 29263302).",
            "molecularProfile": {
                "id": 29148,
                "profileName": "CA9 over exp"
            },
            "therapy": {
                "id": 6827,
                "therapyName": "SLC-0111 + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11104,
                    "pubMedId": 29263302,
                    "title": "Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29263302"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13589,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CID613034 resulted in reduced colony formation, apoptotic activity, and inhibition of migration in glioblastoma cells in culture (PMID: 28453552).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6846,
                "therapyName": "CID613034",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11212,
                    "pubMedId": 28453552,
                    "title": "Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28453552"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13590,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JR-AB2-011 resulted in tumor growth inhibition, increased apoptotic activity, and improved survival of glioblastoma cell line xenograft models (PMID: 28453552).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6847,
                "therapyName": "JR-AB2-011",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11212,
                    "pubMedId": 28453552,
                    "title": "Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28453552"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13770,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "TERT mutations aid in the diagnosis of glioblastoma (NCCN.org).",
            "molecularProfile": {
                "id": 29108,
                "profileName": "TERT mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13896,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, combination of Vorolanib (X-82) and Afinitor (everolimus) resulted in stable disease in a patient with glioblastoma (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2588-2588).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1272,
                "therapyName": "Everolimus + Vorolanib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11342,
                    "pubMedId": null,
                    "title": "Phase I study of X-82, an oral dual anti-VEGFR/PDGFR tyrosine kinase inhibitor, with everolimus in solid tumors.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2588"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14004,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, an epithelioid glioblastoma patient harboring BRAF V600E treated with Mekinist (trametinib) and Tafinlar (dabrafenib) combination therapy resulted in stable disease, and the patient continued to demonstrate stable disease at least 16 months after initiation of therapy (PMID: 29632053).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11407,
                    "pubMedId": 29632053,
                    "title": "Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29632053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17519,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in significant clinical improvement in a patient with epithelioid glioblastoma harboring BRAF V600E, however, her disease progressed after 3 months of therapy (PMID: 31217909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15565,
                    "pubMedId": 31217909,
                    "title": "Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31217909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14188,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1390 inhibited Atm activity, sensitized glioblastoma cell lines to radiotherapy in culture, and demonstrated efficacy in mouse models of glioblastoma (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).",
            "molecularProfile": {
                "id": 20966,
                "profileName": "ATM positive"
            },
            "therapy": {
                "id": 7032,
                "therapyName": "AZD1390",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11499,
                    "pubMedId": null,
                    "title": "AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A104"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14190,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TP53 mutant glioblastoma cells demonstrated increased sensitivity to radiosensitization by AZD1390 treatment compared to TP53 wild-type cells in culture (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 7032,
                "therapyName": "AZD1390",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11499,
                    "pubMedId": null,
                    "title": "AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A104"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14222,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, treatment with a clinically active dose of VAL-083 resulted in improved overall survival (7.9 vs 2.9 months, HR=0.341, p=0.003) compared to an inactive dose in Avastin (bevacizumab)-refractory glioblastoma multiforme patients (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 2061-2061; NCT01478178).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2921,
                "therapyName": "VAL-083",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11544,
                    "pubMedId": null,
                    "title": "Dianhydrogalactitol in bevacizumab-refractory GBM: Further analysis of a phase 1-2 trial.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2061"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14225,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, SurVaxM (SVN53-67/M57-KLH) treatment resulted in a 6-month progression-free survival rate of 96.3% (53/55) measured from diagnosis and 62.8% (27/43) from first immunization, and an overall survival rate at 12 months of 90.9% (30/33) from diagnosis and 70.8% (17/24) from first immunization in patients with newly diagnosed glioblastoma with median tumor Birc5 (survivin) expression of 12% (J Clin Oncol 36, 2018 (suppl; abstr 2041); NCT02455557).",
            "molecularProfile": {
                "id": 18137,
                "profileName": "BIRC5 positive"
            },
            "therapy": {
                "id": 7049,
                "therapyName": "SurVaxM",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11549,
                    "pubMedId": null,
                    "title": "Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.",
                    "url": "http://abstracts.asco.org/214/AbstView_214_220133.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14391,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a glioblastoma patient harboring amplifications in CD274, PDCD1LG2, JAK2, MET, and MDM2 was sensitive to the combined therapy of Opdivo (nivolumab) and Cometriq (cabozantinib), demonstrating a partial response at four weeks (PMID: 29902298).",
            "molecularProfile": {
                "id": 29995,
                "profileName": "CD274 amp JAK2 amp MDM2 amp MET amp PDCD1LG2 amp"
            },
            "therapy": {
                "id": 2067,
                "therapyName": "Cabozantinib + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11631,
                    "pubMedId": 29902298,
                    "title": "Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29902298"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14468,
            "approvalStatus": "Phase 0",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase 0 trial, Adavosertib (MK-1775) demonstrated safety and preliminary efficacy, resulted in good brain tumor penetration and Wee1 pathway inhibition in intraoperatively collected tumor samples from patients with first-recurrence glioblastoma (PMID: 29798906).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11639,
                    "pubMedId": 29798906,
                    "title": "Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29798906"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14471,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of DCVax-L to standard therapy resulted in a median overall survival (mOS) of 23.1 months in the intended to treat group (n=331) of patients with newly diagnosed glioblastoma, with a mOS of 34.7 months in patients with methylated MGMT (n?=?131) (PMID: 29843811; NCT00045968).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5205,
                "therapyName": "DCVax-L",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11642,
                    "pubMedId": 29843811,
                    "title": "First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29843811"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14521,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Gliovac (ERC 1671) adminstered with Leukine (sargramostim) as an adjuvant demonstrated low toxicity and resulted in an improved 40-week overall survival rate of 77% (n=9) vs. 10% (n=39) with historical controls in patients with recurrent glioblastoma multiforme (PMID: 25865468).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7163,
                "therapyName": "Gliovac + Sargramostim",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11725,
                    "pubMedId": 25865468,
                    "title": "First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25865468"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14935,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, WT2725 treatment resulted in survival for more than a year in 33% (7/21) of patients with progressive or recurrent glioblastoma, with 3 patients survived over 18 months, 2 survived over 2 years (both in complete radiologic remission) (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 2066-2066; NCT01621542).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7196,
                "therapyName": "WT2725",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11817,
                    "pubMedId": null,
                    "title": "Initial phase 1 study of WT2725 dosing emulsion in patients with advanced malignancies.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2066#affiliationsContainer"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14960,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ningetinib inhibited Met phosphorylation in tumor tissue, resulted in prolonged median survival time and significantly increased life-span in cell line xenograft models of glioblastoma (Cancer Res 2014;74(19 Suppl):Abstract nr 1755).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 7232,
                "therapyName": "Ningetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11861,
                    "pubMedId": null,
                    "title": "CT053PTSA, a novel c-MET and VEGFR2 inhibitor, potently suppresses angiogenesis and tumor growth",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/1755"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15095,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited Ros1 signaling, suppressed 3D spheroid formation of glioblastoma cells barboring GOPC-ROS1 in culture (PMID: 30171048).",
            "molecularProfile": {
                "id": 10684,
                "profileName": "GOPC - ROS1"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12493,
                    "pubMedId": 30171048,
                    "title": "Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30171048"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15096,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited Ros1 signaling, suppressed 3D spheroid formation of glioblastoma cells barboring GOPC-ROS1 in culture (PMID: 30171048).",
            "molecularProfile": {
                "id": 10684,
                "profileName": "GOPC - ROS1"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12493,
                    "pubMedId": 30171048,
                    "title": "Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30171048"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15097,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited Ros1 signaling, suppressed 3D spheroid formation of glioblastoma cells barboring GOPC-ROS1 in culture (PMID: 30171048).",
            "molecularProfile": {
                "id": 10684,
                "profileName": "GOPC - ROS1"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12493,
                    "pubMedId": 30171048,
                    "title": "Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30171048"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15098,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorlatinib (PF-06463922) inhibited Ros1 signaling, suppressed 3D spheroid formation of glioblastoma cells barboring GOPC-ROS1 in culture, and inhibited tumor growth, prolonged survival in cell line xenograft models (PMID: 30171048).",
            "molecularProfile": {
                "id": 10684,
                "profileName": "GOPC - ROS1"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12493,
                    "pubMedId": 30171048,
                    "title": "Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30171048"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15214,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cell line xenograft models expressing PTPRZ1-MET treated with Xalkori (crizotinib) demonstrated inhibition of Met phosphorylation and increased phosphorylation of Cdk2, and reduced tumor volume, although to a lesser degree than when treated with Bozitinib (PLB-1001) (PMID: 30343896).",
            "molecularProfile": {
                "id": 30833,
                "profileName": "PTPRZ1 - MET"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12846,
                    "pubMedId": 30343896,
                    "title": "Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30343896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15303,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with secondary glioblastoma co-harboring PTPRZ1-MET and MET deletion exon 14 demonstrated a partial response when treated with Bozitinib (PLB-1001) (PMID: 30343896; NCT02978261).",
            "molecularProfile": {
                "id": 30967,
                "profileName": "PTPRZ1 - MET MET del exon14"
            },
            "therapy": {
                "id": 7469,
                "therapyName": "Bozitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12846,
                    "pubMedId": 30343896,
                    "title": "Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30343896"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15362,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, treatment with PVSRIPO by convection-enhanced delivery in patients with recurrent grade IV malignant glioma demonstrated safety and resulted in a median overall survival (OS) of 12.5 months, compared to 11.3 months in historical controls, and a 24-month and 36-month OS of 21% (95% CI, 11 to 33), compared to 14% and 4%, respectively in historical controls (PMID: 29943666; NCT02986178).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7569,
                "therapyName": "PVSRIPO",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13110,
                    "pubMedId": 29943666,
                    "title": "Recurrent Glioblastoma Treated with Recombinant Poliovirus.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29943666"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15629,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (NAVIGATE), Vitrakvi (larotrectinib) treatment resulted in evidence of effect by imaging in a patient with glioblastoma multiforme harboring AFAP1-NTRK1 (Cancer Res 2017;77(13 Suppl):Abstract nr LB-302).",
            "molecularProfile": {
                "id": 31095,
                "profileName": "AFAP1 - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13475,
                    "pubMedId": null,
                    "title": "Potential role of larotrectinib (LOXO-101), a selective pan-TRK inhibitor, in NTRK fusion-positive recurrent glioblastoma",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/LB-302"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15630,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (NAVIGATE), Vitrakvi (larotrectinib) treatment resulted in evidence of effect by imaging in a patient with glioblastoma multiforme harboring BCR-NTRK2 (Cancer Res 2017;77(13 Suppl):Abstract nr LB-302).",
            "molecularProfile": {
                "id": 31123,
                "profileName": "BCR - NTRK2"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13475,
                    "pubMedId": null,
                    "title": "Potential role of larotrectinib (LOXO-101), a selective pan-TRK inhibitor, in NTRK fusion-positive recurrent glioblastoma",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/LB-302"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15965,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iniparib in combination with radiotherapy and Temodar (temozolomide) resulted in improved median overall survival (22 months, HR=0.44) compared to historical control in patients with newly diagnosed glioblastoma multiforme (PMID: 30131387).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7838,
                "therapyName": "Iniparib + Radiotherapy + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14085,
                    "pubMedId": 30131387,
                    "title": "Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30131387"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16066,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, PTEN mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who did not respond to anti-PD-1 therapy, with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who responded (odds ratio=0.85, p=0.0063), with 23 PTEN mutations identified in 32 non-responders and 3 in 13 responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31465,
                "profileName": "IDH1 wild-type PTEN mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16067,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, PTEN mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who did not respond to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who responded (odds ratio=0.85, p=0.0063), with 23 PTEN mutations identified in 32 non-responders and 3 in 13 responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31465,
                "profileName": "IDH1 wild-type PTEN mut"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16068,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31466,
                "profileName": "BRAF mut IDH1 wild-type"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16069,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31466,
                "profileName": "BRAF mut IDH1 wild-type"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16070,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31467,
                "profileName": "IDH1 wild-type PTPN11 mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16071,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31467,
                "profileName": "IDH1 wild-type PTPN11 mut"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16073,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, response to Keytruda (pembrolizumab) or Opdivo (nivolumab) therapy was not predicted by RNA expression levels of CD274 (PD-L1) in glioblastoma patients (PMID: 30742119).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16842,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WSD0922 treatment resulted in dose-dependent inhibition of EGFRvIII phosphorylation and downstream signaling in patient-derived xenograft (PDX) models of glioblastoma multiforme, and growth inhibition in ex-vivo PDX (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1326).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 8206,
                "therapyName": "WSD0922",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14952,
                    "pubMedId": null,
                    "title": "WSD0922: A BBB penetrable EGFR/EGFRVIII inhibitor for the treatment of GBM and metastatic CNS tumor",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17071,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Relatlimab (BMS-986016), in combination with Urelumab (BMS-986016), resulted in a medium overall survival of 7 months, as compared to 8 months with Relatlimab (BMS-986016) alone, or 14 months with Urelumab (BMS-986016) alone, in patients with glioblastoma (J of Clin Oncol 37, 2019 (suppl; abstr 2017); NCT02658981).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8402,
                "therapyName": "Relatlimab + Urelumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15192,
                    "pubMedId": null,
                    "title": "Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.2017"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17520,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Zelboraf (vemurafenib) treatment resulted in tumor regression as confirmed by MRI after 3-weeks of treatment in a patient with epithelioid glioblastoma harboring BRAF V600E (PMID: 31217909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15565,
                    "pubMedId": 31217909,
                    "title": "Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31217909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18027,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Zelboraf (vemurafenib) treatment resulted in a partial response 1 week after treatment in a patient with epithelioid type glioblastoma harboring BRAF V600E, although the patient soon passed due to complications (PMID: 31386052).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15942,
                    "pubMedId": 31386052,
                    "title": "Response of metastatic glioma to vemurafenib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31386052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17521,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with epithelioid glioblastoma harboring BRAF V600E continued to response as Cotellic (cobimetinib) was added to Zelboraf (vemurafenib) treatment (PMID: 31217909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15565,
                    "pubMedId": 31217909,
                    "title": "Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31217909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17522,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Ibrance (palbociclib) in combination with Zelboraf (vemurafenib) resulted in clinical improvement and stable disease in a patient with epithelioid glioblastoma harboring BRAF V600E and homozygous deletion of CDKN2A and CDKN2B, however, his disease progressed after 10 weeks on treatment (PMID: 31217909).",
            "molecularProfile": {
                "id": 32674,
                "profileName": "BRAF V600E CDKN2A del CDKN2B del"
            },
            "therapy": {
                "id": 4129,
                "therapyName": "Palbociclib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15565,
                    "pubMedId": 31217909,
                    "title": "Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31217909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18036,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial,  KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 60% (6/10) of patients with TP53 wild-type, MDM2 amplified glioblastoma, with a median duration of 1.8 months (PMID: 31359240; NCT01723020).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15968,
                    "pubMedId": 31359240,
                    "title": "Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31359240"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18782,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OMO-1 inhibited tumor growth in a cell line xenograft model of HGF autocrine glioblastoma (Cancer Res 2018;78(13 Suppl):Abstract nr 4791).",
            "molecularProfile": {
                "id": 25620,
                "profileName": "HGF positive"
            },
            "therapy": {
                "id": 8846,
                "therapyName": "OMO-1",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16455,
                    "pubMedId": null,
                    "title": "OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models",
                    "url": "https://cancerres.aacrjournals.org/content/78/13_Supplement/4791"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19210,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AOH1160 inhibited growth of glioblastoma cells from patients in culture (PMID: 29967249).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8907,
                "therapyName": "AOH1160",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16726,
                    "pubMedId": 29967249,
                    "title": "The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29967249"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19247,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AsiDNA inhibited survival of glioblastoma cell lines in culture (PMID: 27559053).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8967,
                "therapyName": "AsiDNA",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16843,
                    "pubMedId": 27559053,
                    "title": "Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27559053"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19248,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AsiDNA treatment led to increased sensitivity to Lynparza (olaparib), resulting in decreased survival of glioblastoma cell lines in culture (PMID: 27559053).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8968,
                "therapyName": "AsiDNA + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16843,
                    "pubMedId": 27559053,
                    "title": "Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27559053"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19400,
            "approvalStatus": "Phase 0",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase 0 trial, Kisqali (ribociclib) demonstrated good CNS penetration and inhibited Rb1 phoaphorylation and tumor cell proliferation, resulted in a median progression-free survival of 9.7 week and an overall survival of 7.8 months in patients (n=6) with recurrent glioblastoma with intact Rb1 expression and harboring deletion of CDKN2A or amplification of CDK4 or CDK6 (PMID: 31285369; NCT02933736).",
            "molecularProfile": {
                "id": 16567,
                "profileName": "CDK4 amp RB1 pos"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16988,
                    "pubMedId": 31285369,
                    "title": "A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285369"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19401,
            "approvalStatus": "Phase 0",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase 0 trial, Kisqali (ribociclib) demonstrated good CNS penetration and inhibited Rb1 phoaphorylation and tumor cell proliferation, resulted in a median progression-free survival of 9.7 week and an overall survival of 7.8 months in patients (n=6) with recurrent glioblastoma with intact Rb1 expression and harboring deletion of CDKN2A or amplification of CDK4 or CDK6 (PMID: 31285369; NCT02933736).",
            "molecularProfile": {
                "id": 32265,
                "profileName": "CDK6 amp RB1 pos"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16988,
                    "pubMedId": 31285369,
                    "title": "A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285369"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19403,
            "approvalStatus": "Phase 0",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase 0 trial, Kisqali (ribociclib) demonstrated good CNS penetration and inhibited Rb1 phoaphorylation and tumor cell proliferation, resulted in a median progression-free survival of 9.7 week and an overall survival of 7.8 months in patients (n=6) with recurrent glioblastoma with intact Rb1 expression and harboring deletion of CDKN2A or amplification of CDK4 or CDK6 (PMID: 31285369; NCT02933736).",
            "molecularProfile": {
                "id": 34074,
                "profileName": "CDKN2A del RB1 pos"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16988,
                    "pubMedId": 31285369,
                    "title": "A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285369"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19752,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Plerixafor (AMD3100) treatment following standard chemoradiation in newly-diagnosed glioblastoma patients was well-tolerated, and 93% (27/29) achieved 6 months without progression, with a median progression-free survival of 14.5 months and median overall survival of 21.3 months, and Plerixafor (AMD3100) treatment was associated with decreased relative cerebral blood volume and decreased rate of in-field recurrence (PMID: 31537527; NCT01977677)",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1756,
                "therapyName": "Plerixafor",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17542,
                    "pubMedId": 31537527,
                    "title": "Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31537527"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19917,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Trabedersen (AP 12009) treatment in patients with recurrent or refractory high-grade glioma (including grade IV glioblastoma multiforme or grade III astrocytoma) resulted in responses in 19 (3 complete and 16 partial responses) and stable disease for at least 6 months in 7 of 77 patients in the efficacy population, and a median progression-free survival of 86 days and median overall survival of 432 days (PMID: 31795071; NCT00431561).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2705,
                "therapyName": "Trabedersen",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17587,
                    "pubMedId": 31795071,
                    "title": "Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGF\u03b22-Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31795071"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20439,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (ReACT) trial, addition of Rindopepimut (CDX-110) to Avastin (bevacizumab) resulted in a 6-month progression-free survival of 28% (10/36), compared to 16% (6/17) for control (p=0.12) in patients with relapsed glioblastoma multiforme harboring EGFR V30_R297delinsG (EGFRvIII), and conferred survival advantage (HR=0.53, p=0.01), higher objective response rate (30%, 9/30 vs 18%, 6/34, p=0.38), and longer median duration of response (7.8 vs 5.6 mo) (PMID: 32034072; NCT01498328).",
            "molecularProfile": {
                "id": 32825,
                "profileName": "EGFR V30_R297delinsG"
            },
            "therapy": {
                "id": 9362,
                "therapyName": "Bevacizumab + Rindopepimut",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17842,
                    "pubMedId": 32034072,
                    "title": "Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32034072"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 21208,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells expressing IDH1 R132H were resistant to treatment with Trichostatin (TSA) in culture, demonstrating decreased apoptotic activity and increased cell viability (PMID: 31151327).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 2867,
                "therapyName": "Trichostatin A",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18479,
                    "pubMedId": 31151327,
                    "title": "IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31151327"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21209,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells expressing IDH1 R132H were resistant to treatment with Zolinza (vorinostat) in culture, demonstrating increased cell viability (PMID: 31151327).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18479,
                    "pubMedId": 31151327,
                    "title": "IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31151327"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21210,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells expressing IDH1 R132H were resistant to treatment with Valproic Acid in culture, demonstrating increased cell viability (PMID: 31151327).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 1076,
                "therapyName": "Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18479,
                    "pubMedId": 31151327,
                    "title": "IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31151327"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21211,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of AGI-5198 treatment in glioblastoma cells expressing IDH1 R132H led to decreased resistance to Trichostatin (TSA) treatment in culture, resulting in reduced cell viability (PMID: 31151327).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 9638,
                "therapyName": "AGI-5198 + Trichostatin A",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18479,
                    "pubMedId": 31151327,
                    "title": "IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31151327"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21212,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of AGI-5198 treatment in glioblastoma cells expressing IDH1 R132H led to decreased resistance to Zolinza (vorinostat) treatment in culture, resulting in reduced cell viability (PMID: 31151327).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 9639,
                "therapyName": "AGI-5198 + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18479,
                    "pubMedId": 31151327,
                    "title": "IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31151327"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00054496",
            "title": "Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00301418",
            "title": "Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00492687",
            "title": "Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00669669",
            "title": "Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2556,
                    "therapyName": "O6-benzylguanine",
                    "synonyms": null
                },
                {
                    "id": 2555,
                    "therapyName": "Carmustine + Filgrastim + Plerixafor + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00906516",
            "title": "Neuradiab Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2146,
                    "therapyName": "81C6 + Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00968240",
            "title": "Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00998010",
            "title": "Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3055,
                    "therapyName": "Bortezomib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01052363",
            "title": "OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2109,
                    "therapyName": "Bevacizumab + Fosbretabulin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01067469",
            "title": "Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 2118,
                    "therapyName": "Bevacizumab + Lomustine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01107522",
            "title": "Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar&#174; in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar&#174; and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1142,
                    "therapyName": "Carboxyamidotriazole Orotate  + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 999,
                    "therapyName": "Carboxyamidotriazole Orotate",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01112527",
            "title": "PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 714,
                    "therapyName": "Dacomitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01130077",
            "title": "A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2595,
                    "therapyName": "Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01140568",
            "title": "Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 829,
                    "therapyName": "Nilotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01149850",
            "title": "Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2115,
                    "therapyName": "Bevacizumab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01177397",
            "title": "Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 693,
                    "therapyName": "CC-223",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01238237",
            "title": "Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01260506",
            "title": "Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2277,
                    "therapyName": "Bevacizumab + VB-111",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01266031",
            "title": "Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2110,
                    "therapyName": "Bevacizumab + Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01269424",
            "title": "O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2972,
                    "therapyName": "O6-benzylguanine + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01269853",
            "title": "Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01290263",
            "title": "Amgen 386 for Recurrent Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1219,
                    "therapyName": "Bevacizumab + Trebananib",
                    "synonyms": null
                },
                {
                    "id": 1218,
                    "therapyName": "Trebananib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01331291",
            "title": "Bosutinib in Adult Patients With Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 690,
                    "therapyName": "Bosutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01331616",
            "title": "Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01339039",
            "title": "Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2120,
                    "therapyName": "Bevacizumab + Plerixafor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01349660",
            "title": "Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1178,
                    "therapyName": "Bevacizumab + Buparlisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01386710",
            "title": "Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 2074,
                    "therapyName": "Bevacizumab + Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01421524",
            "title": "Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2358,
                    "therapyName": "CC-122",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01430351",
            "title": "Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8578,
                    "therapyName": "Metformin + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 8577,
                    "therapyName": "Mefloquine + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 8580,
                    "therapyName": "Memantine + Metformin + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 8579,
                    "therapyName": "Mefloquine + Memantine + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 8582,
                    "therapyName": "Mefloquine + Memantine + Metformin + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 8581,
                    "therapyName": "Mefloquine + Metformin + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 8576,
                    "therapyName": "Memantine + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01434602",
            "title": "Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2299,
                    "therapyName": "Everolimus + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01435395",
            "title": "Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2122,
                    "therapyName": "Bevacizumab + Bortezomib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01473901",
            "title": "A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4474,
                    "therapyName": "Buparlisib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01478178",
            "title": "Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2921,
                    "therapyName": "VAL-083",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01478321",
            "title": "Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2115,
                    "therapyName": "Bevacizumab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01508117",
            "title": "Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 649,
                    "therapyName": "Axitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01526837",
            "title": "Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01576666",
            "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1547,
                    "therapyName": "Buparlisib + Sonidegib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01591577",
            "title": "Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2440,
                    "therapyName": "Lapatinib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01607905",
            "title": "Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01621542",
            "title": "Clinical Study of WT2725 in Patients With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 7196,
                    "therapyName": "WT2725",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01672463",
            "title": "Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7151,
                    "therapyName": "OKN-007",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01721577",
            "title": "Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2745,
                    "therapyName": "AXL1717",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01730950",
            "title": "Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01753713",
            "title": "Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 721,
                    "therapyName": "Dovitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01756352",
            "title": "FET-PET for Evaluation of Response of Recurrent GBM to Avastin",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01788280",
            "title": "Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01790503",
            "title": "A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 874,
                    "therapyName": "Pexidartinib",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01800695",
            "title": "Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 976,
                    "therapyName": "Depatuxizumab mafodotin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01811498",
            "title": "Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01814813",
            "title": "Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01837862",
            "title": "A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2134,
                    "therapyName": "Carboplatin + Mebendazole + Temozolomide + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 2133,
                    "therapyName": "Bevacizumab + Irinotecan + Mebendazole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01849146",
            "title": "WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2713,
                    "therapyName": "Adavosertib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01860638",
            "title": "A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 2075,
                    "therapyName": "Lomustine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01870726",
            "title": "Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2461,
                    "therapyName": "Buparlisib + Capmatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01884740",
            "title": "Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1654,
                    "therapyName": "Bevacizumab + Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01891747",
            "title": "A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2115,
                    "therapyName": "Bevacizumab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01894061",
            "title": "NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01903330",
            "title": "ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 1873,
                    "therapyName": "Sargramostim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01904123",
            "title": "A Phase I Trial of WP1066",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2784,
                    "therapyName": "WP1066",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01925573",
            "title": "NOVOTTF-100A+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01931098",
            "title": "Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1469,
                    "therapyName": "Pazopanib + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01933815",
            "title": "Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 2274,
                    "therapyName": "TPI 287",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01934361",
            "title": "Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2500,
                    "therapyName": "Buparlisib + Lomustine",
                    "synonyms": null
                },
                {
                    "id": 2501,
                    "therapyName": "Buparlisib + Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01954576",
            "title": "NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT01975701",
            "title": "A Phase 2 Study of BGJ398 in Patients With Recurrent GBM",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 674,
                    "therapyName": "BGJ398",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01977677",
            "title": "Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1756,
                    "therapyName": "Plerixafor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01986348",
            "title": "Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01989052",
            "title": "Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2075,
                    "therapyName": "Lomustine",
                    "synonyms": null
                },
                {
                    "id": 999,
                    "therapyName": "Carboxyamidotriazole Orotate",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01999270",
            "title": "Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2112,
                    "therapyName": "Bevacizumab + Irinotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02010606",
            "title": "Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02017717",
            "title": "A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02026271",
            "title": "A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4250,
                    "therapyName": "Ad-RTS-IL-12 plus AL",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02038699",
            "title": "A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1687,
                    "therapyName": "ONC201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02047214",
            "title": "Safety and Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2123,
                    "therapyName": "Bevacizumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02052778",
            "title": "A Study of TAS-120 in Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1053,
                    "therapyName": "Futibatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02067156",
            "title": "Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4338,
                    "therapyName": "mipsagargin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02101905",
            "title": "Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 787,
                    "therapyName": "Lapatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02120287",
            "title": "Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02133183",
            "title": "TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02137759",
            "title": "MRSI to Predict Response to RT/TMZ and Vorinostat in GBM",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1077,
                    "therapyName": "Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02146066",
            "title": "Expanded Access Protocol for GBM Patients With Already Manufactured DCVax\u00ae-L Who Have Screen-Failed Protocol 020221",
            "phase": "Expanded access",
            "recruitment": "Available",
            "therapies": [
                {
                    "id": 5205,
                    "therapyName": "DCVax-L",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02152982",
            "title": "Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02157103",
            "title": "A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02179086",
            "title": "Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02197169",
            "title": "DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4407,
                    "therapyName": "DNX-2401",
                    "synonyms": null
                },
                {
                    "id": 4444,
                    "therapyName": "DNX-2401 + interferon gamma",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02238496",
            "title": "Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2194,
                    "therapyName": "Perifosine + Temsirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02285959",
            "title": "Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02311582",
            "title": "MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02311920",
            "title": "Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02315534",
            "title": "A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2057,
                    "therapyName": "Napabucasin",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02327078",
            "title": "A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3059,
                    "therapyName": "Epacadostat + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02336165",
            "title": "Phase 2 Study of MEDI4736 in Patients With Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 2117,
                    "therapyName": "Bevacizumab + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02337491",
            "title": "Pembrolizumab +/- Bevacizumab for Recurrent GBM",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2119,
                    "therapyName": "Bevacizumab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02340156",
            "title": "Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2518,
                    "therapyName": "SGT-53",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02342379",
            "title": "TH-302 in Combination With Bevacizumab for Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2144,
                    "therapyName": "Bevacizumab + Evofosfamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02343406",
            "title": "ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2075,
                    "therapyName": "Lomustine",
                    "synonyms": null
                },
                {
                    "id": 976,
                    "therapyName": "Depatuxizumab mafodotin",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02343549",
            "title": "LCI-NEU-NOV-001 Study of a Device Worn on the Head in Combination With Chemo to Treat Brain Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2115,
                    "therapyName": "Bevacizumab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02345824",
            "title": "Early-Phase Study to Assess Inhibitor LEE011 in Patients With Recurrent Glioblastoma or Anaplastic Glioma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 790,
                    "therapyName": "Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02348255",
            "title": "NovoTTF-100A in Combination With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2371,
                    "therapyName": "Bevacizumab + Carmustine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02365662",
            "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2914,
                    "therapyName": "ABBV-221",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02386826",
            "title": "INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2600,
                    "therapyName": "Bevacizumab + Capmatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02414165",
            "title": "P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 2075,
                    "therapyName": "Lomustine",
                    "synonyms": null
                },
                {
                    "id": 3211,
                    "therapyName": "Toca 511 + Toca FC",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02423525",
            "title": "Safety Study of Afatinib for Brain Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02442297",
            "title": "T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2940,
                    "therapyName": "HER2 sensitized T-cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02465268",
            "title": "Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (ATTAC-II)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7101,
                    "therapyName": "pp65 Dendritic Cell Vaccine + Sargramostim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02478164",
            "title": "Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 877,
                    "therapyName": "Ponatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02498665",
            "title": "A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4320,
                    "therapyName": "DSP-7888",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02510950",
            "title": "Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1873,
                    "therapyName": "Sargramostim",
                    "synonyms": null
                },
                {
                    "id": 2595,
                    "therapyName": "Poly ICLC",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02511405",
            "title": "A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 2276,
                    "therapyName": "VB-111",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02521090",
            "title": "EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1012,
                    "therapyName": "EGFRBi-armed autologous activated T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02525692",
            "title": "Oral ONC201 in Adult Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1687,
                    "therapyName": "ONC201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02526017",
            "title": "Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2840,
                    "therapyName": "Cabiralizumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02530502",
            "title": "Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02573324",
            "title": "A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 976,
                    "therapyName": "Depatuxizumab mafodotin",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02586857",
            "title": "A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1605,
                    "therapyName": "Acalabrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02605746",
            "title": "Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 789,
                    "therapyName": "Ceritinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02607124",
            "title": "Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 790,
                    "therapyName": "Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02617589",
            "title": "Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02619864",
            "title": "mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 991,
                    "therapyName": "Vistusertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02626364",
            "title": "Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 705,
                    "therapyName": "Crenolanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02648633",
            "title": "Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4219,
                    "therapyName": "Nivolumab + Valproic acid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02661282",
            "title": "Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9746,
                    "therapyName": "Autologous CMV-specific CTLs + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02663271",
            "title": "TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02667587",
            "title": "Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer).",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 3724,
                    "therapyName": "Nivolumab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02717962",
            "title": "Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2921,
                    "therapyName": "VAL-083",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02743078",
            "title": "Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02754362",
            "title": "A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2595,
                    "therapyName": "Poly ICLC",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02766699",
            "title": "A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) (CerebralEDV)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5331,
                    "therapyName": "EGFR(V)-EDV-Dox",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02768389",
            "title": "Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02780024",
            "title": "Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02783300",
            "title": "Dose Escalation Study of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6958,
                    "therapyName": "GSK3326595",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02798406",
            "title": "Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4408,
                    "therapyName": "DNX-2401 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02800486",
            "title": "Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02829723",
            "title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2844,
                    "therapyName": "BLZ945",
                    "synonyms": null
                },
                {
                    "id": 5071,
                    "therapyName": "BLZ945 + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02844439",
            "title": "Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 967,
                    "therapyName": "XL647",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02852655",
            "title": "A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma",
            "phase": "Phase 0",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02858895",
            "title": "Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 7142,
                    "therapyName": "MDNA55",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02861898",
            "title": "Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4559,
                    "therapyName": "Cetuximab + Mannitol",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02871843",
            "title": "Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4596,
                    "therapyName": "RRx-001 + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02876003",
            "title": "Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4338,
                    "therapyName": "mipsagargin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02885324",
            "title": "Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02928575",
            "title": "Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 4905,
                    "therapyName": "Sunitinib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02942264",
            "title": "TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5836,
                    "therapyName": "TG02",
                    "synonyms": null
                },
                {
                    "id": 5851,
                    "therapyName": "Temozolomide + TG02",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02968940",
            "title": "Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02974621",
            "title": "Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1971,
                    "therapyName": "Cediranib + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02977780",
            "title": "INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1000,
                    "therapyName": "CC-115",
                    "synonyms": null
                },
                {
                    "id": 5028,
                    "therapyName": "Abemaciclib + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 5029,
                    "therapyName": "Neratinib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02981940",
            "title": "A Study of Abemaciclib in Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03014804",
            "title": "Dendritic Cell-Autologous Lung Tumor Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 5205,
                    "therapyName": "DCVax-L",
                    "synonyms": null
                },
                {
                    "id": 5206,
                    "therapyName": "DCVax-L + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03018288",
            "title": "Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 5221,
                    "therapyName": "Pembrolizumab + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 5220,
                    "therapyName": "Pembrolizumab + Temozolomide + Vitespen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03027388",
            "title": "Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3514,
                    "therapyName": "LB-100",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03047473",
            "title": "Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme (SEJ)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03107780",
            "title": "MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1452,
                    "therapyName": "KRT-232",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03128047",
            "title": "HUMC 1612: Optune NovoTTF-200A System",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2115,
                    "therapyName": "Bevacizumab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03139916",
            "title": "Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5634,
                    "therapyName": "Bavituximab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03149003",
            "title": "A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD201G)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5986,
                    "therapyName": "Bevacizumab + DSP-7888",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03150862",
            "title": "A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2947,
                    "therapyName": "Pamiparib",
                    "synonyms": null
                },
                {
                    "id": 6124,
                    "therapyName": "Pamiparib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03174197",
            "title": "Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5872,
                    "therapyName": "Atezolizumab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03197506",
            "title": "Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5221,
                    "therapyName": "Pembrolizumab + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03216499",
            "title": "HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4146,
                    "therapyName": "PT2385",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03223103",
            "title": "Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT03234712",
            "title": "A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6975,
                    "therapyName": "ABBV-321",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03250299",
            "title": "Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4908,
                    "therapyName": "BAL101553",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03277638",
            "title": "Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03295396",
            "title": "ONC201 in Adults With Recurrent High-grade Glioma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1687,
                    "therapyName": "ONC201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03296696",
            "title": "Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6261,
                    "therapyName": "AMG 596",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03332355",
            "title": "Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6443,
                    "therapyName": "PAC-1 + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03341806",
            "title": "Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03344250",
            "title": "Phase I EGFR BATs in Newly Diagnosed Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1012,
                    "therapyName": "EGFRBi-armed autologous activated T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03347617",
            "title": "Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03367715",
            "title": "Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03382977",
            "title": "Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6662,
                    "therapyName": "VBI-1901",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03405792",
            "title": "Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune\u00ae) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5221,
                    "therapyName": "Pembrolizumab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03412877",
            "title": "Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9195,
                    "therapyName": "Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL",
                    "synonyms": null
                },
                {
                    "id": 9196,
                    "therapyName": "Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03422094",
            "title": "Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 6699,
                    "therapyName": "Ipilimumab + NeoVax + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 6700,
                    "therapyName": "NeoVax + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03423628",
            "title": "A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7032,
                    "therapyName": "AZD1390",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03425292",
            "title": "A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03426891",
            "title": "Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6703,
                    "therapyName": "Pembrolizumab + Temozolomide + Vorinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03430791",
            "title": "Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Bevacizumab-na\u00efve, Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03449381",
            "title": "This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8523,
                    "therapyName": "BI 907828",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03452579",
            "title": "Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2111,
                    "therapyName": "Bevacizumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03452930",
            "title": "EDO-S101 for MGMT Unmethylated Glioblastoma (nGBM)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6104,
                    "therapyName": "Tinostamustine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03463265",
            "title": "ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7409,
                    "therapyName": "Lomustine + Nab-Rapamycin",
                    "synonyms": null
                },
                {
                    "id": 3380,
                    "therapyName": "Nab-Rapamycin",
                    "synonyms": null
                },
                {
                    "id": 7408,
                    "therapyName": "Nab-Rapamycin + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 7407,
                    "therapyName": "Bevacizumab + Nab-Rapamycin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03491683",
            "title": "INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7071,
                    "therapyName": "Cemiplimab + INO-5401 + INO-9012 + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03493932",
            "title": "Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03514069",
            "title": "Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                },
                {
                    "id": 6913,
                    "therapyName": "Ruxolitinib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03535350",
            "title": "Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 6945,
                    "therapyName": "Ibrutinib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03596086",
            "title": "HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7303,
                    "therapyName": "HSV-Tk + Valacyclovir",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03603405",
            "title": "HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7040,
                    "therapyName": "HSV-Tk",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03605550",
            "title": "A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5407,
                    "therapyName": "PTC596",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03607643",
            "title": "A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 2183,
                    "therapyName": "Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin",
                    "synonyms": "Bevacizumab + FOLFIRINOX"
                },
                {
                    "id": 7247,
                    "therapyName": "Bevacizumab + Cannabidiol + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin",
                    "synonyms": "Bevacizumab + Cannabidiol + FOLFIRINOX"
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 7248,
                    "therapyName": "Bortezomib + Cannabidiol",
                    "synonyms": null
                },
                {
                    "id": 7249,
                    "therapyName": "Cannabidiol + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 7250,
                    "therapyName": "Cannabidiol + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03636477",
            "title": "A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7315,
                    "therapyName": "Ad-RTS-IL-12 plus AL + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03637764",
            "title": "Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7075,
                    "therapyName": "Atezolizumab + Isatuximab",
                    "synonyms": null
                },
                {
                    "id": 6331,
                    "therapyName": "Isatuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03657576",
            "title": "Trial of C134 in Patients With Recurrent GBM (C134-HSV-1)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9748,
                    "therapyName": "C134-HSV-1",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03661723",
            "title": "Pembrolizumab and Reirradiation in Bevacizumab Na\u00efve and Bevacizumab Resistant Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2119,
                    "therapyName": "Bevacizumab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03681028",
            "title": "Feasibility of Individualized Therapy for Recurrent GBM",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT03688178",
            "title": "DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab (DERIVe)",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 7732,
                    "therapyName": "pp65 Dendritic Cell Vaccine + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 7733,
                    "therapyName": "pp65 Dendritic Cell Vaccine + Temozolomide + Varlilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03696355",
            "title": "Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2018,
                    "therapyName": "GDC-0084",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03707457",
            "title": "Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8138,
                    "therapyName": "MK-4166 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 3059,
                    "therapyName": "Epacadostat + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03726515",
            "title": "CART-EGFRvIII + Pembrolizumab in GBM",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7495,
                    "therapyName": "CART-EGFRvIII + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03732352",
            "title": "18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 660,
                    "therapyName": "Osimertinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03743662",
            "title": "Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03782415",
            "title": "Study to Evaluate Ibudilast and TMZ Combo Treatment in Recurrent GBM",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 8215,
                    "therapyName": "Ibudilast + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03797326",
            "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03856099",
            "title": "TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2515,
                    "therapyName": "Tanibirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03893487",
            "title": "Fimepinostat in Treating Brain Tumors in Children and Young Adults (PNOC016)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 709,
                    "therapyName": "CUDC-907",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03896568",
            "title": "Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4407,
                    "therapyName": "DNX-2401",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03919071",
            "title": "Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03961971",
            "title": "Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8396,
                    "therapyName": "MBG453 + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03970447",
            "title": "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2075,
                    "therapyName": "Lomustine",
                    "synonyms": null
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03973918",
            "title": "Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03975829",
            "title": "Pediatric Long-Term Follow-up and Rollover Study",
            "phase": "FDA approved",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03995706",
            "title": "Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3227,
                    "therapyName": "Sacituzumab govitecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04003649",
            "title": "IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8520,
                    "therapyName": "Anti-IL13RA2 CAR T cells + Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8521,
                    "therapyName": "Anti-IL13RA2 CAR T cells + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04013672",
            "title": "Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8566,
                    "therapyName": "Montanide ISA 51 + Pembrolizumab + Sargramostim + SurVaxM",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04015700",
            "title": "Neoantigen-based Personalized DNA Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8570,
                    "therapyName": "GNOS-PV01 + INO-9012 + Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8569,
                    "therapyName": "GNOS-PV01 + INO-9012 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04049669",
            "title": "Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8654,
                    "therapyName": "Cyclophosphamide + Etoposide + Indoximod",
                    "synonyms": null
                },
                {
                    "id": 8655,
                    "therapyName": "Indoximod + Lomustine + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 8653,
                    "therapyName": "Indoximod + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 2976,
                    "therapyName": "Indoximod",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04051606",
            "title": "Phase II Study of Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04074785",
            "title": "Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9205,
                    "therapyName": "Abemaciclib + Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04089449",
            "title": "A Study of PRT811 in Participants With Advanced Solid Tumors, Gliomas and Myelofibrosis",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9227,
                    "therapyName": "PRT811",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04116658",
            "title": "First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma (ROSALIE)",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9126,
                    "therapyName": "EO2401",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04118036",
            "title": "Abemaciclib + Pembrolizumab In Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 4242,
                    "therapyName": "Abemaciclib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04195139",
            "title": "Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM (NUTMEG)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3724,
                    "therapyName": "Nivolumab + Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04197934",
            "title": "WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8206,
                    "therapyName": "WSD0922",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04201873",
            "title": "Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9097,
                    "therapyName": "DC tumor cell lysate vaccine + Poly ICLC",
                    "synonyms": null
                },
                {
                    "id": 9096,
                    "therapyName": "DC tumor cell lysate vaccine + Pembrolizumab + Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04216329",
            "title": "Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9172,
                    "therapyName": "Selinexor + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04221503",
            "title": "Niraparib/TTFields in GBM",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 832,
                    "therapyName": "Niraparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04225039",
            "title": "Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9247,
                    "therapyName": "INCAGN01876 + INCMGA00012",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04254419",
            "title": "Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT04259450",
            "title": "Study to Assess AFM24 in Advanced Solid Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5856,
                    "therapyName": "AFM24",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04295759",
            "title": "INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 6876,
                    "therapyName": "INCB7839",
                    "synonyms": null
                }
            ]
        }
    ]
}